

CURRICULUM VITAE Lucia De Franceschi

Education

- **1991.** Medical degree at the University of Verona: 110/110 cum laude (presenter prof R Corrocher)
- **1997.** Specialization in Internal Medicine, University of Verona: 50/50 cum laude (presenters: prof G De Sandre and prof R. Corrocher).

Scientific and professional history

- **1991-1992. Research fellow** at the Department of Physiology, Harvard Medical School, Boston, MA, USA
- **1993 to 1997.** During her internship in Internal Medicine (Dept. of Medicine, Section of Internal Medicine, University of Verona she spent **3 months per year as visiting researcher** Unité de Recherche en genetique moleculaire et en Hematologie, INSERMU91, Hopital H Mondor, Université de Creteil, France, Direttore: prof. Y. Beuzard e presso Laboratory of Gene Therapy, Hopital S Louis, Paris, France, Director: prof. Y. Beuzard.
- **1997-2000.** She was a member of the **European steering Committee-BIOMED 2- PL95** on project entitled: "Reactivation of fetal hemoglobin synthesis as a means to improve the quality of life of patients with hemoglobinopathies".
- **01.03.1998-30.08.1998. Visiting Instructor in Pathology**, Department of Pathology, Children's Hospital, Harvard Medical School, Boston, MA, USA. Director: prof. C Brugnara.
- **September 1998, she became Researcher in Internal Medicine (MED09)** with a permanent position in the Dept. of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona.
- **From 2003** until now she is in the panel review of the **Cochrane cystic fibrosis and genetic disorders group** on sickle cell disease and related clinical and therapeutic issues.
- **From 2002** until now she is ia member of the teaching staff of the PhD program on Clinical Proteomics and she is in charged for the educational and tutorial programs.
- In **February 2006** she obtained the qualification of associated professor in Internal Medicine (MED/09) and in **October 2006** she got the permanent position Dept. of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona.
- From Nov. 2000 to Nov. 2011 and from Feb 2015 up-to now, she had an **annual appointment as Associated Researcher** Depts of Pathology and Laboratory of Medicine, Children's Hospital, Harvard Medical School, Boston, MA, USA.
- From 2006-2023 she was Associated professor of Internal Medicine, Dept. of Medicine, Section of Internal Medicine, University of Verona.
- **2019-2022.** She was one of the EMA identified expert for the following dossiers: 2019- Xyndari in SCD patients; 2022: Reblozyl in NTDT patients.

CURRENT NATIONAL AND INTERNATIONAL POSITIONS

- **1 Oct 2023- Full professor of Medicine, Dept. of Medicine, Section of Internal Medicine, University of Verona.**
- 2006-2023: Associate Professor of Internal Medicine, Department of Medicine, Section of Internal Medicine, University of Verona
- January 2023–present: Coordinator of the PhD program in Biomolecular Medicine, University of Verona
- 2015–present: Member of the teaching staff of the PhD program in Biomolecular Medicine, University of Verona
- October 2024–present: Director of the Specialty School in Allergy and Clinical Immunology, University of Verona
- 2000–present: Director of the Research Laboratory: Red Cell Pathology and Erythropoiesis, at LURM-UNIVR.
- 2018-present: Research Associate at the Dept of Laboratory of Medicine, Children's Hospital, Harvard Medical School, Boston; MA, USA (Annex 3: letter from the Department Director, Prof. Orah S Platt)
- **June 2024- member of the advisory board of the European Hematology Association (EHA).**

PREVIOUS NATIONAL AND INTERNATIONAL POSITIONS

- 2022-2024 QA Coordinator for Internationalization at the Department of Medicine.
- 2015-2020 Coordinator of the PhD program in Biomolecular Medicine, University of Verona
- 2019-2020 Rector's Delegate for Postgraduate Studies at UNIVR
- 2001-2016 Research Associate at the Department of Laboratory of Medicine, Children's Hospital, Harvard Medical School, Boston; MA, USA (Annex 3: Letter from the Department Director, Professor Orah S. Platt).
- 2006-2015 - Member of the teaching staff for the PhD program in Clinical Genomics and Proteomics at UNIVR, which later became the PhD program in Biomolecular Medicine, UNIVR.
- 2003–2007: Dean's Delegate for Internationalization, Faculty of Medicine, UNIVR
- 1993–2007: Visiting researcher (1 month/year) at the Red Cell Pathology Laboratory, Hôpital H Mondor, Créteil, France (director: Prof. Y. Beuzard) and then at the Gene Therapy Laboratory, Centre Hayem, Hôpital Saint-Louis, Paris; France (director: Prof. Y. Beuzard).
- 1999–2006: Permanent Assistant Professor in Internal Medicine (MED09) at the Department of Clinical and Experimental Medicine, University of Verona
- 1998–1999: Visiting Instructor in Pathology, Departments of Pathology and

Laboratory of Medicine, Children's Hospital, Harvard Medical School, Boston; MA, USA.

- 1992–1993: Fellowship in Cell Physiology: Harvard Medical School, Boston; MA, USA (Directors: Prof. DC Tosteson and Prof. C Brugnara)

Grants and research projects

She obtained the following grants:

- **FIRB-project** 2001 (2003-2006)- RBNE01XHME-MIUR "Proteomic approach to erythroid cells and erythropoiesis" (PI).
- **PRIN (2004):** # 2004065788 MIUR. "Functional proteomic approach to membrane transport system in normal and diseased red cells: role of K-Cl cotransport" (PI).
- **PRIN (2006)** # 2006063929 (MIUR): "Proteomic analysis of erythroid precursors in anemias associated with iron overload" (PI).
- **PRIN (2008):** # 2008N73CJ5 (Italian Ministry of Research): " Molecular mechanisms of hepcidin inhibition in iron deficiency, hypoxia and erythropoietic expansion: relevance to genetic and acquired iron disorders" (PI).
- **PRIN (2012)** #20128PNX83" Study of the molecular mechanisms of erythropoiesis for the identification of therapeutic targets" (PI).
- **PRIN (2020)** #2020Z22PM7:" Understanding diserythropoiesis to identify new therapeutic mechanisms in hereditary anemias" (PI).
- **PRIN (2022)** # 2022E87XJW:" Understanding the role of macrophages at single cell level in sickle cell related pulmonary hypertension" (PI-national coordinator)
- **PNRR PNRR-POC-2023-12378393 (2023-2026):** "The impact of a novel a novel therapeutic approach for inherited erythroid disorders based on the precise editing of the TFR2 gene" (PI).
- **Telethon grant GPP07007** (2007-2012) Analysis of functional and post- translational modifications in abnormal red cells from neuroacanthocytosis'. (PI).
- **Telethon grant GPP13005 (2014-2017):**" Lyn core on neuroacanthocytosis". (PI)
- **Telethon grant GPP20116 (2021-2024):**" Identification of Druggable Pro-Resolving Mechanisms in Sickle cell Disease" (focus on SCD cardiomyopathy) (PI).
- **2008 John Grooms Wellcome Trust and the Advocacy for neuroacanthocytosis patients** (UK) project title:" Intracellular signaling in red cells from neuroacanthocytosis" (PI).
- **2012-2015 the Advocacy for neuroacanthocytosis patients Wellcome Trust**(UK) project title:" Signal transduction in red cells of patients with chorea- acanthocytosis: the Lyn connection" (PI).
- **2017-2018 the Advocacy for neuroacanthocytosis patients Wellcome Trust**(UK) Targeting the link between autophagy and Lyn to identify new therapeutic options in chorea-acanthocytosis" (PI).
- **2018-2020 the Advocacy for neuroacanthocytosis patients Wellcome Trust** (UK):" Modulation of cell signaling by targeting Lyn as New Therapeutic Options InChorea-Acanthocytosis (PI).
- **2020-2021 the Advocacy for neuroacanthocytosis patients Wellcome Trust**(UK). Understanding the functional link between kinome and proteostasis dysfunction in chorea-acanthocytosis.(PI).
- **2020** Phd Grant PON-FSE-FESR (research innovation 2014-2020) (PON R&I) -Action

I.1- Innovative Phd students with an industrial character – 36th cycle, Title of the project: "Development and clinical validation of new highly automated technologies for in vitro molecular diagnostics".

- **2021-2022 the Advocacy for neuroacanthocytosis patients Wellcome Trust.** Understanding the functional role of Vps13a in mouse model of chorea- acanthocytosis. (UK) (PI).
- **2023-2025 The Advocacy for neuroacanthocytosis patients Wellcome Trust.** Integrate metabolomic and interactome mapping in mice genetically lacking chorein (Vps13a^{-/-} mice). (UK) (PI).
- **Telethon grant GMR25T2032 (2026 – 2029) titled "A NOVEL THERAPEUTIC APPROACH TARGETING PRO-RESOLVING MECHANISMS IN THE CARDIOMYOPATHY OF SICKLE CELL DISEASE"**
- **PNRR-POC-2023-12378393 (2024-2027).** The impact of a novel therapeutic approach for inherited erythroid disorders based on precise editing of Trf2 (996.420 euro). (PI).

PI research grants with biopharma or private institutions (n=6)

- **2005-2010 Research grant:** Characterization of ICAs Gardos channel inhibitors (*Icagen, USA*) (PI).
- **2015-2018 Research grant** " Functional characterization of Glut 1 inhibitor in β thalassemia " (*Roche, Switzerland*) (PI).
- **2016-2020 Research grant** - "understanding the effects of new anti-sickling molecules and rADAMST13" (*Baxalta, now Takeda, Japan*) (PI).
- **2015- Research grant** "Metabolic impact of PK-activator in hemoglobinopathies and rare anemias" (*Agios, USA, active*) (PI).
- **2021- Research grant** " Characterization of w-3 fatty acid mixture on sickle cell disease (Afimmune Limited, Ireland; **active**) (PI).
- **2022- Research grant- Bristol:** Impact of Luspatercept of humanized mouse model for SCD (**active, PI**)
- **2023 Fondazione For Anemia- Convenzione-progetto di ricerca:** " A Single Center, Pilot Clinical Investigation of Safety and Efficacy of Hypoxic Red Blood Cells Manufactured with Hemanext ONE[®] System in Patients with β -Thalassemia Requiring Chronic Transfusion" (**active**). (PI).

Co-PI (n=4):

- 1996-1997. **Telethon grant #E491** titled: " Molecular mechanisms of cell dehydration in sickle cell disease and β -thalassemia regulation of KCC1 cotransport in normal and diseased erythrocytes" as co-PI.
- 1997-1998. **Telethon grant # E791:** " Molecular mechanisms of cell dehydration in sickle cell disease and β -thalassemia regulation of KCC1 cotransport in normal and diseased erythrocytes" as co-PI.
- **NIH grant** (2002-2007) co-PI "Red cell homeostasis and red cell magnesium content in SCA".
- Since 2014, member of the European Project **PROTEOSTASIS (BM1307) -EU COST Action** (Wp3) (www.cost-proteostasis.eu).

Partecipante Unita' di Ricerca (n=2):

1. **PRIN project** (2002): #200262119 MIUR. "Proteomic approach on red cell membrane oxidative damage in hemoglobinopathies".

PRIN project (1999): # 9906311132_004: " Characterization of transport systems involved in cell

volume regulation in congenital red blood cell disorders.

Lucia De Franceschi is part of the teaching staff of the European School of Hematology. She is a member of the Cochrane's reviewer group on sickle cell disease. She is associated editor for the American Journal of Hematology since 2007. She is part of the editorial Board of BLOOD since 2016.

H-F ACTOR: 52 (Scopus)

Number of citation: 10.635 (Scopus)

Total IF: 18446.37

Papers on IF journal >12: 43 papers; IF journal <12>10: 21 papers.

Tabella Papers				
RIVISTA	Quartile SJR 2020	<i>n</i>	IF Journal	IF totale paper(s)
Circulation	Q1	1	39.91	39.91
Hepatology	Q1	1	33.0	33.0
BLOOD	Q1	26	23.0	598
Lancet Hematology	Q1	1	17.7	17.7
Hemasphere	Q1	7	14.6	102.2
Autophagy	Q1	1	14.6	14.6
J Clin Invest	Q1	6	13.6	81.6
Redox Biology	Q1	1	11.9	11.9
J Thromb Haemost	Q1	1	10.4	10.4
Am J Hematology	Q1	19	10.3	195.7
Cochrane Database Syst Rev	Q1	4	9.4	37.6
Am J Gastroenterology	Q1	1	8.1	8.1
Free Radical Biol & Med	Q1	6	8.2	49.2
Haematologica	Q1	25	7.9	197.5
Blood Advances	Q1	2	7.1	14.2
Cell Report	Q1	1	6.9	6.9
Clin Chem Lab Med	Q1	1	6.8	6.8
Antioxidants	Q2	5	6.6	33
J Clin Invest Insight	Q1	2	6.1	12.2
Antioxidant Redox Signaling	Q1	2	6.1	12.2
European J of Internal Medicine	Q1	4	6.1	24.4
Liver International	Q1	1	5.2	5.2
Modern Pathology	Q1	1	5.5	5.5
Acta Neuropathol Comm	Q1	2	5.7	5.7
BMT Journal	Q1	1	5.2	5.2
Annals of Emergency Medicine	Q1	1	5.4	5.4
J Cell Physiol	Q1	1	5.546	5.546
J Biol Chem	Q1	2	5.486	10.972
J Med Chem	Q1	1	5.484	5.848
J Cyst Fibrosis	Q1	1	5.482	5.482
J Cell Mol Med	Q1	1	5.31	5.31
Int J Obes	Q1	1	5.095	5.095
Exp Op Invest Drug	Q1	1	5.08	5.08
Frontiers in Medicine	Q1	1	5.058	5.058

Int J Mol Sci	Q1	1	4.9	4.9
Biochem J	Q1	2	4.779	9.558
Frontiers in Physiology	Q1	1	4.755	4.755
Annals of NY Academy of Science	Q1	1	4.728	4.728
Am J Physiol-Lung Cell Mol Physiol	Q1	1	4.659	4.659
Front Mol Biosci	Q1	1	4.62	4.62
Oxidative medicine and cellular longevity	Q1	2	4.5	9.0
J Neuroscience	Q1	1	4.0	4.0
FASEB J	Q1	2	4.4	8.8
Sci Report	Q1	1	4.37	4.37
J Transl Med	Q1	1	4.206	4.206
J Hypertension	Q1	1	4.171	4.171
Int J Cardiol	Q1	1	4.164	4.164
Eur J of Physiology- Pflugers Arch	Q1	1	4.084	4.084
J. of Proteomics	Q2	1	4.044	4.044
Thromb Research	Q1	1	3.994	3.994
Diagnostics	Q1	1	3.992	3.992
Sem Hematol	Q1	1	3.989	3.989
Proteomics	Q1	2	3.929	7.858
British Journal of Haematol	Q1	2	3.9	7.80
Am J Reprod Immunol	Q1	1	3.886	3.886
Seminars in Thromb and Haemost	Q1	1	3.693	3.693
Orphanet Journal of Rare Disease	Q1	3	3.687	11.061
BBA general subjects	Q2	1	3.67	3.67
Eur J Clin Invest	Q1	1	3.6	3.6
Med J Hematol	Q2	1	3.623	3.623
PLoS One	Q1	6	3.534	21.204
Am J Physiol (Cell Physiol)	Q1	4	3.485	13.940
Diagnostics	Q1	1	3.24	3.24
Pain Practice	Q1	1	3.183	3.183
Electrophoresis	Q2	1	3.161	3.161
Transfusion	Q2	3	3.30	9.9
Exp Haematol	Q1	1	3.084	3.084
Exp Physiol	Q2	1	2.969	2.969
J Clin Med	Q1	3	2.9	8.7
Current Opinion in Hematology	Q1	3	2.9	8.7
J Pain Reserch	Q1	1	2.76	2.76
Proteomics Clinical Application	Q2	2	2.683	5.366
Vox Sanguinis	Q2	1	2.585	2.585
Eur J Gastroent & Hepatology	Q2	1	2.566	2.566
J Memb Biol	Q2	1	2.482	2.482
Blood Transfusion	Q2	3	2.4	7.2
Minerva Pediatrica	Q3	1	2.387	2.387
Blood Cell Mol Disease	Q2	3	2.331	6,993
Drugs New Perspect	Q2	1	2.305	2.305
Acta Pediatrica	Q2	1	2.299	2.299
J Lab Clin Med	Q3	1	2.193	2.193

Epidemiol Prev	Q3	1	1.901	1.901
Med Hypothesis	Q3	1	1.375	1.375
Hemoglobin	Q4	1	1.274	1.274
Cell Mol Biol	Q3	1	1.176	1.176
Data in Brief	Q4	2	1.13	2.26
Pediatric reports	Q3	1	0.968	0.968
Sante	Q3	1	0.294	0.294
Hematologie	Q3	2	0.136	0.272
IF TOTALE		215		1846.37

Papers

- 1) Brugnara C, **De Franceschi L**. The effect of cell age and phenylhydrazine on the cation transport properties of rabbit erythrocytes. *J. Cell Physiol.* 154: 271-280, 1993.
- 2) Brugnara C, **De Franceschi L**, Alper SL. Ca^{2+} -activated K^+ transport in erythrocytes: comparison of binding and transport inhibition by scorpion toxins. *J. Biol. Chem.* 268:8760-8768, 1993.
- 3) Brugnara C, **De Franceschi L**, Alper SL. Inhibition of Ca^{2+} -activated K^+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. *J. Clin. Invest.* 92: 520-526, 1993.
- 4) Olivieri O, **De Franceschi L**, De Gironcoli M, Girelli D, Corrocher R. Potassium loss and cell dehydration of stored erythrocytes following incubation in autologous plasma: role of K/Cl cotransport system. *Vox Sang.* 65: 95-102, 1993.
- 5) **De Franceschi L**, Saadane N, Alper SL, Brugnara C, Beuzard Y. Treatment with oral clotrimazole blocks Ca^{2+} -activated K^+ transport and reverses erythrocyte dehydration in transgenic SAD mice: model for therapy of sickle cell disease. *J. Clin. Invest.* 93: 1670-1676, 1994.
- 6) Olivieri O, **De Franceschi L**, Cappellini MD, Girelli D, Corrocher R, Brugnara C. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias. *Blood* 84: 315-320, 1994.
- 7) Brugnara C, **De Franceschi L**, Armsby CC, Saadane N, Trudel M, Beuzard Y, Rittenhouse A, Rifai N, Platt O, Alper SL. A new therapeutic approach for sickle cell disease: blockade of the red cell Ca^{2+} -activated K^+ channel by clotrimazole. *The Annals of the New York Academy of Science*, 763:262-271, 1995.
- 8) **De Franceschi L**, Beuzard Y, Brugnara C. Sulphydryl oxidation and activation of red cell K/Cl cotransport in the SAD mouse, transgenic model for sickle cell anemia. *Am. J. Physiol* 269 (Cell Physiol: 38) C899-C906, 1995.
- 9) **De Franceschi L**, Olivieri O, Girelli D, Bernich P, Lupo A, Corrocher R. Red cell cation transport in uremic anemia: evidence for an increased K/Cl cotransport activity. Effects of dialysis and erythropoietin treatment. *Eur. J. Clin. Invest.* 25: 762-768, 1995.
- 10) Brugnara C, Armsby CC, **De Franceschi L**, Crest M, Euclaire MFM, Alper SL. Ca^{2+} -activated K^+ channels of human and rabbit erythrocytes display distinctive patterns of inhibition by venom peptide toxins. *J. Membrane Biol.* 147: 71-82, 1995.
- 11) Girelli D, Olivieri O, **De Franceschi L**, Corrocher R, Bergamaschi G, Cazzola M. A linkage between hereditary hyperferritinemia not related to iron overload and autosomal dominant congenital cataract. *Brit. J. Haematol.* 90: 931-935, 1995.
- 12) Girelli D, Corrocher R, Bisceglia L, Olivieri O, **De Franceschi L**, Zelante L, Gasparini P. Molecular basis of recently described hereditary hyperferritinemia-cataract syndrome: a mutation in the iron responsive element of ferritin L-subunit gene ("the Verona mutation").

Blood 86: 4050-4053, 1995

- 13) Russo C, Olivieri O, Girelli D, Azzini M, Stanzial AM, Guarini P, Friso S, **De Franceschi L**, Corrocher R. Omega-3 PUFA supplementation and ambulatory blood pressure monitoring parameters in mild essential hypertensive patients. *J.Hypertension* 13: 1823-1826, 1995.
- 14) **De Franceschi L**, Rouyer-Fessard P, Alper SL, Jouault H, Brugnara C, Beuzard Y. Combination therapy of clotrimazole, hydroxyurea and erythropoietin in a thalassemic mouse: a model for human therapy. *Blood* 87: 1186-1195, 1996.

- 15) **De Franceschi L**, Brugnara C, Jouault H, Beuzard Y. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. *Blood* 88: 2738-2744, 1996.
- 16) **De Franceschi L**, Fumagalli L, Olivieri O, Corrocher R, Lowell CA, Berton G. Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K-Cl cotransport. *J. Clin. Invest.* 99:220-227, 1997.
- 17) **De Franceschi L**, Beuzard Y, Brugnara C. Dietary magnesium supplementation ameliorates anemia in a mouse model of β -thalassemia. *Blood* 90: 1283-1290, 1997.
- 18) **De Franceschi L**, Bachir D, Galacteros F, Tchernia GJ, Cynober T, Alper SL, Platt O, Beuzard Y, Brugnara C. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. *J. Clin. Invest.* 100: 1847-1852, 1997.
- 19) **De Franceschi L**, Olivieri O, Miraglia del Giudice E, Perrotta S, Corrocher R, Iolascon A. Anion transport and K-Cl cotransport in hereditary spherocytosis associated with different membrane defects. *Am. J. Hematol.* 55: 121-128, 1997.
- 20) Olivieri O, **De Franceschi L**, Bordin L, Manfredi M, Miraglia de Giudice E, Perrotta S, De Vito M, Guarini P, Corrocher R. Increased membrane protein phosphorylation and anion transport activity in chorea-acanthocytosis. *Haematologica* 82: 648-653, 1997.
- 21) **De Franceschi L**, Turrini F, Miraglia del Giudice E, Perrotta S, Olivieri O, Corrocher R, Mannu F, Iolascon A. Decrease band 3 anion transport activity and band 3 clusterization in congenital dyserythropoietic anemia type II. *Exp. Haematol.* 26: 869-873, 1998.
- 22) **De Franceschi L**, Cappellini MD, Olivieri O, Graziadei G, Corrocher R, Beuzard Y, Brugnara C. The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with β -thalassemia intermedia. *Haematologica* 83: 118-125, 1998.
- 23) Vandorpe DH, Shmukler BE, Jiang L, Lim B, Maylie J, Adelman JP, **De Franceschi L**, Cappellini MD, Brugnara C, Alper SL. cDNA cloning and functional characterization of the mouse Ca^{2+} activated K^{+} channel, *miK1*. *J. Biol. Chem.* 273: 21542-21553, 1998.
- 24) **De Franceschi L** and Beuzard Y. Red blood cell indices, cation content and membrane cation transport. *Hemoglobin* 22: 493-500, 1998.
- 25) **De Franceschi L**, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R, Hebbel RP, Brugnara C. Deferipone therapy in homozygous human β -thalassemia removes erythrocyte membrane free iron reduces K-Cl cotransport activity. *J. Lab. Clin. Med.* 133: 64-69, 1999.
- 26) Su W, Shmukler BE, Chernovaa MN, Stuart-Tilley AK, **De Franceschi L**, Brugnara C, Alper SL. Mouse K-Cl cotransporter *KCC1*: cloning, mapping, pathological expression and functional regulation. *Am. J. Physiol.* 277 (Cell Physiol 46) C899- C912, 1999.
- 27) Beuzard Y, **De Franceschi L**, Vitoux D, Rouyer-Fessard P, Henri A. Towards therapies of hemoglobin disorders, targeting the erythrocyte. *Hematologie* 5: 60-75, 1999.

- 28) **De Franceschi L**, Brugnara C, Rouyer- Fessard P, Jouailt H, Beuzard Y. Formation of dense erythrocyte in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and additive benefit of combining oral clotrimazole and magnesium therapies. *Blood* 94: 4307-4313, 1999.
- 29) **De Franceschi L**, Bachir D, Galacteros F, Tchernia G, Cynober T, Neuber D, Beuzard Y, Brugnara C. Oral magnesium reduces the number of painful days in patients with sickle cell disease. *Brit. J. Haematol.* 108: 284-289, 2000.
- 30) **De Franceschi L**, Fattovich G, Turrini F, Ayl K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Haemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C infection: role of membrane oxidative damage. *Hepatology* 31: 997-1004, 2000.
- 31) Bennekou P, **De Franceschi L**, Pedersen O, Lian L, Asakura T, Evans G, Brugnara C, Christophersen P. Treatment with NS3623, a novel Cl⁻-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach to sickle cell disease. *Blood* 97: 1451-1457, 2001.
- 32) Brugnara C, **De Franceschi L**, Beuzard Y. Erythrocyte- active agents and treatment of sickle cell disease. *Sem. Hematol* 38: 324-332, 2001.
- 33) **De Franceschi L**, Villa-Moruzzi E, Fumagalli L, Brugnara C, Turrini F, Motta R, Veghini E, Corato C, Alper SL, Berton G. K-Cl cotransport modulation by intracellular Mg in erythrocytes from mice bred for low and high Mg levels. *Am. J. Physiol. (Cell Physiol)* 281: C1385-C1395, 2001.
- 34) Brugnara C, **L De Franceschi**, P Bennekou, SL Alper, P Christophersen. Novel therapies for prevention of erythrocyte dehydration in sickle cell anemia. *Drugs News Perspect* 14: 208-220, 2001.
- 35) Riddington C, **De Franceschi L**. Drugs for preventing red cell dehydration in people with sickle cell disease. *Cochrane Database Syst Rev* 4: CD003426, 2002.
- 36) Stocker JW, **De Franceschi L**, McNaughton-Smith GA, Corrocher R, Beuzard Y, Brugnara C. ICA-17043, a novel Gardos channel blocker, prevents sickle red cell dehydration in vitro and in vivo in SAD mice. *Blood* 101: 2412-2418, 2003.
- 37) **De Franceschi L**, Baron A, Scarpa A, Adrie C, Janin A, Barbi S, Kister J, Rouyer- Fessard P, Corrocher R, Leboulch P, Beuzard Y. Inhaled nitric oxide protects transgenic SAD Mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. *Blood* 102:1087-1096, 2003.
- 38) **De Franceschi L**, Zaia B, Corrocher R. Diagnosis and initial treatment of acute events in sickle cell disease. *Haematologica* 88: (Suppl. 6) 59-62, 2003
- 39) **De Franceschi L**, Olivieri O, Corrocher R. Erythrocyte aging in neurodegenerative disorders. *Cell Mol Biol*, 50: 179-185, 2004

- 40) **De Franceschi L**, Corrocher R. Established and experimental treatments for sickle cell disease. *Haematologica*, 89: 348-356, 2004.
- 41) Favalli MN, **De Franceschi L**, Bassetto AM, Bambara LM, Mansueto G, Corrocher R. Selective intra-arterial Terlipressin infusion stops acute lower gastrointestinal bleeding: a case report and review of the literature. *Eur. J. Gastroenterology & Hepatol*, 16:1059-1061, 2004.
- 42) Riddington C, **De Franceschi L**. Drugs for preventing red cell dehydration in people with sickle cell disease. *Cochrane Database Syst Rev* 4, 2004.
- 43) **De Franceschi L**, Turrini F, Honczarenko M, Ayi K, Rivera A, Fleming MD, Law T, Mannu F, Kuypers FA, Bast A, van der Vijgh WJF, Brugnara C. In vivo reduction of erythrocyte oxidant stress in a murine model of β -thalassemia. *Haematologica*, 89:1287-1298, 2004.
- 44) **De Franceschi L**, Finco G, Vassanelli A, Zaia B, Ischia S, Corrocher R. A pilot study on the efficacy of ketorolac plus tramadol infusion in management of sickle cell pain combined with erythrocytapheresis in treatment of acute severe vaso-occlusive crisis. *Haematologica* 89: 1389-1391, 2004
- 45) Mallozzi C, **De Franceschi L**, Brugnara C, Di Stasi AMM. Protein phosphatase 1 is tyrosine phosphorylated and inactivated by peroxynitrite in erythrocyte through the *src* family kinase *fgr*. *Free Radical Biology & Medicine* 38: 1625-36, 2005
- 46) Roncada P, Cretich M, Fortin R, Agosti S, **De Franceschi L**, Greppi G, Turrini F, Carta F, Turri S, Levi M, Chiari M. Acrylamide-agarose copolymers: improved resolution of high molecular-mass proteins in 2D electrophoresis. *Proteomics* 5:2331-2339, 2005
- 47) **De Franceschi L**, Rivera A, Fleming MD, Honczarenko M, Peters LL, Gascard P, Mohandas N, Brugnara C. Evidence of a protective role of the Gardos channel against hemolysis in murine spherocytosis. *Blood* 106: 1454-9, 2005
- 48) **De Franceschi L**, Sada S, Andreoli A, Angheben A, Marocco S, Bisoffi Z. Sickle cell disease and hyperreactive malarial splenomegaly (HMS) in young immigrants from Africa. *Blood*, [letter] 106: 4415-7, 2005.
- 49) Perrotta S, Borriello A, Scaloni A, **De Franceschi L**, Brunati AM, Turrini F, Nigro V, Miraglia del Giudice E, Nobili B, Conte ML, Rossi F, Iolascon A, Donella-Deana A, Zappia V, Poggi V, Anong W, Low P, Narla M, Della Ragione F. The N-Terminal 11 amino acids of human erythrocyte band 3 are critical for aldolase binding and protein phosphorylation: implications for band 3 function. *Blood* 106: 4359-66, 2005.
- 50) Sada S, Benini L, Pavan C, Favalli MN, Mansueto G, Capelli P, Corrocher R, **De Franceschi L**. Ischemic colitis sustained by sickle-cell-trait in young adult patient. *Am J Gastroenterol*, [letter] 100: 2818-21, 2005.
- 51) **De Franceschi L**, Villa-Moruzzi E, Biondani A, Siciliano A, Brugnara C, Alper SL, Lowell CA, Berton G. Regulation of K-Cl cotransport by protein phosphatase 1a in mouse

- erythrocytes. *Pflugers Archiv-European Journal of Physiology*, 451:760-8, 2006.
- 52) Brugnara C, **De Franceschi L**. New therapeutic approaches to sickle cell disease. *Hematologie* 12: 239-245, 2006.
- 53) Guido M, **De Franceschi L**, Zagni I, Leandro G, Felder M, Corrocher R, Rugge M, Cavallini G, Lanza C, Capelli P, Fattovich G. Effects of interferon plus Ribavirin Treatment on NF- κ B, TGF- β 1 and metalloproteinase activity in chronic hepatitis C. *Modern Pathology*, 19: 1047-54, 2006.
- 54) **De Franceschi L**, Malpeli G, Scarpa A, Janin A, Muchitsch EM, Roncada P, Leboeuf C, Corrocher R, Beuzard Y, Brugnara C. Protective effects of S-Nitroso-Albumin on lung injury induced by hypoxia/reoxygenation in a mouse model of sickle cell disease. *Am. J. Physiol- Lung Cellular and Molecular Physiology* 291: L457-65, 2006.
- 55) Scambi C, Guarini P, **De Franceschi L**, Bambara LM. Can 5-Methyltetrahydrofolate modify the phospholipids fatty acid pattern in cystic fibrosis pediatric patients? *J Cyst Fibros* 5: 197-9, 2006.
- 56) Rivera A, **De Franceschi L**, Peters LL, Gascard P, Mohandas N, Brugnara C. Effect of complete 4.1R deficiency on ion transport properties of murine erythrocytes. *Am. J. Physiol. (Cell Physiol)*, 291: C880-6, 2006.
- 57) **De Franceschi L**, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A, Camaschella C. Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia. *Haematologica* 91: 1336-1342, 2006.
- 58) Brugnara C, **de Franceschi L** [New Therapeutic approaches to sickle cell disease] *Sante* 16: 263-8, 2006
- 59) Filippini A, Villa G, Corrocher R, **De Franceschi L**. Acute hemolytic anemia with acanthocytosis associated with high dose misoprostol for medical abortion. *Annals of Emergency Medicine*, 50: 289-291, 2007
- 60) **De Franceschi L**, Ronzoni L, Cappellini MD, Cimmino F, Siciliano A, Alper SL, Servedio V, Pozzobon C, Iolascon A. K-Cl cotransport (KCC) plays an important role in normal and β thalassaemic erythropoiesis. *Haematologica* 92:1319-1326, 2007
- 61) **De Franceschi L**. Platt OS, Malpeli G, Janin A, Scarpa A, Leboeuf C, Beuzard Y, Payen E, Brugnara C. Protective effects of phosphodiesterase-4 (PDE4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. *FASEBJ*, 22: 1849-1860, 2008.
- 62) McNaughton-Smith GA, Burns JF, Stocker JW, Rigdon GC, Creech C, Arrington S, Shelton T, **De Franceschi L**. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. *J Med Chem* 51: 976-82, 2008
- 63) Nathalie Sabaa, **Lucia De Franceschi**, Philippe Bonnin, Yves Castier, Giorgio Malpeli, Haythem Debbabi, Ariane Galaup, Micheline Maier-Redelsperger, Sophie Vandermeersch, Aldo Scarpa, Anne Janin, Bernard Levy, Robert Girot, Yves Beuzard, Christophe Leboeuf,

- Annie Henri, Stéphane Germain, Jean-Claude Dussaule and Pierre-Louis Tharaux: Endothelin receptor antagonism prevents vaso-occlusion induced hemodynamic changes, reduces renal and lung damage and abrogates hypoxia-induced mortality in experimental sickle cell disease. *J Clin Invest*, 118: 1924-1933, 2008
- 64) Biondani A, Turrini F, Carta F, Matte' A, Filippini A, Siciliano A, Beuzard Y, **De Franceschi L**. Heat shock protein-27, 70 and peroxiredoxin –II show molecular chaperone function in sickle red cells: evidence from transgenic sickle cell mouse model. *Proteomics - Clinical Applications*, 2: 706-719, 2008
- 65) Lippi G, **De Franceschi L**, Salvagno GL, Pavan C, Montagnana M, Guidi GC. Cardiac troponin T during sickle cell crisis. *Int J Cardiol*, Epub, Jul 2008
- 66) Lippi G, **De Franceschi L**, Salvagno GL, Montagnana M, Guidi GC. Estimation of glomerular filtration rate by the modification of diet in renal disease (MDRD) equation in patients with sickle cell disease. *Clin Chem Lab Med* 46: 1200, 2008
- 67) **De Franceschi L**, Biondani A, Carta F, Turrini F, Laudanna C, Deana R, Brunati AM, Turreta L, Iolascon A, Perrotta S, Elson A, Bulato C, Brugnara C. PTP ϵ has a critical role in signaling transduction pathways and phosphoprotein network topology in red cells. *Proteomics*, 8: 4695- 708, 2008
- 68) Pantaleo A, Ferru E, Giribaldi G, Mannu F, Carta F, Matte' A, **De Franceschi L**, Turrini F. Selective phosphorylation of oxidized and underglycosylated erythrocyte membrane band 3 facilitates its recruitment from large membrane clusters. *Biochemical J* 418: 359-367, 2009
- 69) Scambi C, **De Franceschi L**, Guarini P, Poli F, Siciliano A, Pattini P, Biondani A, LaVerde V, Bortolami O, Turrini F, Carta F, D'Orazio C, Assael BM, Faccini G, Bambara LM. Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial. *PLoS ONE*. 2009;4(3):e4782. Epub 2009 Mar 11.
- 70) Iolascon A, De Falco L, Borgese F, Esposito MR, Avvisati RA, Izzo P, Piscopo C, Guizouarn H, Biondani A, Pantaleo A, **De Franceschi L**. A novel erythroid anion exchange variant (Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis. *Haematologica* 94: 1049-1059, 2009
- 71) Pantaleo A, **De Franceschi L**, Ferru E, Vono R, Turrini F. Current knowledge about functional roles of phosphorylative changes of membrane proteins in normal and diseased red cells. *J Proteomic* 73: 445-55, 2010
- 72) Siciliano A, Turrini F, Bertoldi M, Matte' A, Pantaleo A, Olivieri O, **De Franceschi L**. Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with sickle cell disease. *Blood Cells Mol Dis*, 44: 233-42, 2010
- 73) Matte' A, Low PS, Turrini F, Bertoldi M, Campanella ME, Pantaleo A, Spano D, Siciliano A, **De Franceschi L**. Peroxiredoxin-2 (Prx2) expression is increased in β thalassemic mouse red cells but displaced from the membrane as marker of oxidative stress. *Free Radical Biology & Medicine* 49: 457-66, 2010.

- 74) Del Monte L, Manfredi R, Oliviero O, **De Franceschi L**. Sick cell-related acute abdominal painful crisis complicating the clinical management of a cocaine-packer. *Am J Hematol*, Epub may 24, 2010
- 75) Scambi C, La Verde V, **De Franceschi L**, Barausse G, Poli F, Benedetti F, Sorio M, Deriu F, Roncada P, Bortolami O, Turrini F, Caramaschi P, Stranieri C, Bambara LM, Biasi D. Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H. *PLoS One* 5: e12162, 2010
- 76) Siciliano A, Malpeli G, Platt OS, Lebouef C, Janin A, Scarpa A, Olivieri O, Amato E, Corrocher R, Beuzard Y, **De Franceschi L**. Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sick cell hepatopathy. *Haematologica* 96: 24-32, 2011
- 77) **De Franceschi L**, Bosello S, Scambi C, Biasi D, De Sanctis M, Caramaschi P, Pelugo G, La Verde V, Bambara LM, Ferraccioli GF. Proteome analysis of biological fluids from autoimmune-rheumatological disorders. *Proteomics - Clinical Applications* 5: 78-89, 2011
- 78) **De Franceschi L**, Cappellini MD, Olivieri O. Thrombosis and sick cell disease. *Seminars in Thrombosis & Hemostasis* 37: 226-236, 2011
- 79) **De Franceschi L**, Bertoldi M, De Falco L, Santos Franco S, Ronzoni L, Turrini F, Colancecco A, Camaschella C, Cappellini MD, Iolascon A. Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in β thalassemic erythropoiesis. *Haematologica* 96: 1595-604, 2011.
- 80) **De Franceschi L**, Tomelleri C, Matte A, Brunati AM, Bovee-Geurts PH, Bertoldi M, Lasonder E, Tibaldi E, Danek A, Walker RH, Jung HH, Bader B, Siciliano A, Ferru E, Mohandas N, Bosman GJCGM. Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. *Blood* 118: 5652-63, 2011
- 81) **De Franceschi L**, Scardoni G, Tomelleri C, Danek A, Walker RH, Jung HH, Bader B, Mazzucco S, Dotti MT, Siciliano A, Pantaleo A, Laudanna C. Computational identification of phospho-tyrosine sub-networks related to acanthocyte generation in neuroacanthocytosis. *PLoS One* 7: e31015, 2012.
- 82) Wieschhaus A, Khan A, Zaidi A, Rogalin H, Hanada T, Liu F, **De Franceschi L**, Brugnara C, Rivera A, Chishti AH. Calpain-1 knockout reveals broad effects on erythrocyte deformability and physiology. *Biochemical J*, 448: 141-152, 2012
- 83) **De Franceschi L**, Franco RS, Bertoldi M, Brugnara C, Matte A, Siciliano A, Wieschhaus AJ, Chishti AH, Joiner CH. Pharmacological inhibition of calpain-1 prevents red cell dehydration and reduces Gardos channel activity in a mouse model of sick cell disease. *FASEB J* 2012 Oct 19 doi: 12-217836.
- 84) Matte A, Bertoldi M, Mohandas N, An X, Bugatti A, Brunati AM, Rusnati M, Tibaldi E, Siciliano A, Turrini F, Perrotta S, **De Franceschi L**. Membrane Association of

peroxiredoxin-2 in red cells is mediated by n-terminal cytoplasmic domain of band 3. *Free Radical Biol Med* 55: 27-35, 2013

- 85) Andolfo I, Alper SL, Delaunay J, Auriemma C, Russo R, Asci R, Esposito MR, Sharma AK, Shmukler BE, Brugnara C, **De Franceschi L**, Iolascon A. Missense mutations in the ABCB6 transporter cause dominant familial pseudohyperkalemia. *Am J Hematology* 88: 66-78, 2013.
- 86) Liu J, Zhang J, Ginzburg Y, Li H, Xue F, **De Franceschi L**, Chasis JA, Mohandas N, An X. Quantitative analysis of murine terminal erythroid differentiation: a novel method to study normal and disordered erythropoiesis. *Blood* 121:e43-49, 2013.
- 87) Delmonte L, Zamo A, Cantini M, **De Franceschi L**. An unusual case of sarcoidosis in an adult patient with sickle cell disease: management with methotrexate and low dose of steroid. *Am J Hematol* 88: 43, 2013 (Letter).
- 88) Laperchia C, Allegra Mascaro AL, Sacconi L, Andrioli A, Matte A, **De Franceschi L**, Grassi-Zucconi G, Bentivoglio M, Buffelli M, Pavone FS. Two-photon microscopy imaging of thy1GFP-M transgenic mice: a novel animal model to investigate brain dendritic cell subsets in vivo. *PLoS One* 8: e56144, 2013.
- 89) Vinchi F, **De Franceschi L**, Ghigo A, Townes T, Cimino J, Silengo L, Hirsch E, Altruda F, Tolosano E. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. *Circulation* 127: 1317-29, 2013.
- 90) Delmonte L, Cantini M, Olivieri O, **De Franceschi L**. Immunoglobulin-resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. *Transfusion* 53: 688-89, 2013
- 91) Andolfo I, Alper SL, **De Franceschi L**, Auriemma C, Russo R, De Falco L, Vallefucio F, Esposito MR, Vandorpe DH, Shmukler BE, Narayan R, Montanaro D, D'Armiento M, Vetro A, Limongelli I, Zuffardi O, Glader BE, Schrier SL, Brugnara C, Stewart GW, Delaunay J, Iolascon A. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. *Blood* 121: 3925-35, 2013.
- 92) Cecchini MP, Pellegrini C, Bassetto MA, Osculati F, Sbarbati A, Marcolini L, Pegoraro M, Fontana R, **De Franceschi L**. Might *Helicobacter pylori* infection be associated with distortion of taste perception? *Med Hypotheses*. 2013 Sep;81(3):496-9.
- 93) **De Franceschi L**, Bertoldi M, Matte A, Santos Franco S, Pantaleo A, Ferru E, Turrini F. Oxidative stress and β -thalassemic erythroid cells behind the molecular defect. *Oxid Med Cell Longev* 2013: 985210, 2013
- 94) Matte A, Sola L, Chiari M, Tomelleri C, Consonni R, Turrini F, **De Franceschi L**. Performance of a novel sieving matrix of Poly(vinyl alcohol)ACRYLAMIDE copolymer in electrophoretic separations of high molecular weight proteins from red cell membrane. *Electrophoresis* 19: doi10.1002, 2013.
- 95) **De Franceschi L**. Everything you wanted to know about the pathophysiology of sickle cell

- disease. *Pediatric Reports* 5: 71-74, 2013.
- 96) Santos Franco S, De Falco L, Ghaffari S, Brugnara C, Sinclair DA, Mattè A, Iolascon A, Mohandas N, Bertoldi M, An X, Siciliano A, Rimmelé P, Cappellini MD, Michan S, Zoratti E, Janin A, **De Franceschi L**. Resveratrol accelerates erythroid maturation by activation of FOXO3 and ameliorates anemia in beta-thalassemic mice. *Haematologica*. 99: 267-75, 2014.
- 97) **De Franceschi L**, Bosman GJ, Mohandas N. Abnormal red cell features associated with hereditary neurodegenerative disorders: the neuroacanthocytosis syndromes. *Curr Opin Hematol* 21: 201-9, 2014.
- 98) Forni GL, Finco G, Graziadei G, Balocco M, Rigano P, Perrotta S, Olivieri O, Cappellini MD, **De Franceschi L**. Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department. *Orphanet J Rare Dis* 9: 91, 2014
- 99) Vencato E, Manfredi R, Zamo A, Chilosi M, Beccari S, **De Franceschi L**. A rare disorder in an orphan disease: Kikuchi-Fujimoto disease in a young adult patient with sickle cell anemia. *Am J Hematol* 89: 1151-2, 2014.
- 100) Matte A, Pantaleo A, Ferru E, Turrini F, Bertoldi M, Lupo F, Siciliano A, Zoon H, **De Franceschi L**. The novel role of peroxiredoxin-2 in red cell membrane protein homeostasis and senescence. *Free Radical Biol Med* 76: 80-8, 2014.
- 101) Than NN, Soe HHK, Palaniappan SK, Abas ABL, **De Franceschi L**. Magnesium for treating sickle cell disease. *Cochrane database of Systematic Reviews* 2014: CD011358, 2014
- 102) Scambi C, Ugolini S, Jokiranta TS, **De Franceschi L**, Bortolami O, La Verde V, Guarini P, Caramaschi P, Ravagnani V, Martignoci G, Colato C, Pedron S, Benedetti F, Sorio M, Poli F Biasi D. Local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis generating study. *PLoS One* 10: e0114856; 2015
- 103) Cluitmans JC; Tomelleri C; Yapici Z; Dinkla S; Bovee-Geurts P; Chokkalingam V; **De Franceschi L**; Brock R; Bosman GJ; Abnormal red cell structure and function in neuroacanthocytosis *PLoS One* 10: e01255890. Doi 10.1371/journal.pone.0125580; 2015
- 104) Kalish B, Matte A, Andolfo I, Iolascon A, Weinberg O, Ghigo A, Cimino J, Siciliano A, Hirsch E, Federti E, Puder M, Brugnara C, **De Franceschi L**. Dietary w-3 fatty acids protect against vasculopathy in a transgenic mouse model for sickle cell disease. *Haematologica* 100: 870-80; 2015
- 105) **De Franceschi L**; Mura P; Schweiger V; Vencato E; Quaglia FM; Delmonte L; Evangelista M; Polati E; Olivieri O; Finco G; Fentanyl buccal tablet: a new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease. *Pain Pract* 26: doi 10.1111/papr.12313; 2015
- 106) Matte A, De Falco L, Iolascon A, Mohandas N, An, X, Siciliano A, Leboeuf C, Janin A, Bruno M, Choi SY, Kim DW, **De Franceschi L**. The interplay between peroxiredoxin-2

and nuclear erythroid factor 2 is important in limiting oxidative mediated dysfunction in β -thalassemic erythropoiesis. *Antioxidant Redox Signaling* Epub Jul 14; 2015

- 107) Lupo F, Russo R, Iolascon A, Ieluzzi D, Siciliano A, Toniutto P, Matté A, Piovesan S, Raffetti E, Turrini F, Dissegna D, Donato F, Alberti A, Zuliani V, Fattovich G, **De Franceschi L**. Protease inhibitors-based therapy induces acquired spherocytic-like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. *Liver Int.* 2016 Jan;36(1):49-58.
- 108) Dalle Carbonare L, Matte' A, Valenti MT, Siciliano A, Mori A, Schweiger V, Zampieri G, Perbellini L, **De Franceschi L**. Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. *Blood.* 2015 Nov 12;126(20):2320-8.
- 109) Bellelli R, Federico G, Matte' A, Colecchia D, Iolascon A, Chiariello M, Santoro M, **De Franceschi L**, Carlomagno F. NCOA4 Deficiency Impairs Systemic Iron Homeostasis. *Cell Rep.* 2016 Jan 26;14(3):411-421. doi:
- 110) Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica.* 2016 Feb;101(2):115-208.
- 111) Pantaleo A, Ferru E, Pau MC, Khadjavi A, Mandili G, Mattè A, Spano A, **De Franceschi L**, Pippia P, Turrini F. Band 3 Erythrocyte Membrane Protein Acts as Redox Stress Sensor Leading to Its Phosphorylation by p (72) Syk. *Oxid Med Cell Longev.* 2016;2016:6051093.
- 112) Cluitmans JC, Gevi F, Siciliano A, Matte A, Leal JK, **De Franceschi L**, Zolla L, Brock R, Adjobo-Hermans MJ, Bosman GJ. Red Blood Cell Homeostasis: Pharmacological Interventions to Explore Biochemical, Morphological and Mechanical Properties. *Front Mol Biosci.* 2016 Mar 29;3:10.
- 113) Andolfo I, Russo R, Manna F, De Rosa G, Gambale A, Zouwail S, Detta N, Pardo CL, Alper SL, Brugnara C, Sharma AK, **De Franceschi L**, Iolascon A. Functional characterization of novel ABCB6 mutations and their clinical implications in familial pseudohyperkalemia. *Haematologica.* 2016 Aug;101(8):909-17.
- 114) Russo R, Andolfo I, Manna F, De Rosa G, De Falco L, Gambale A, Bruno M, Mattè A, Ricchi P, Girelli D, **De Franceschi L**, Iolascon A. Increased levels of ERFE-encoding FAM132B in patients with congenital dyserythropoietic anemia type II. *Blood.* 2016 Oct 6;128(14):1899-1902.
- 115) Veneri D, Facchinelli D, Vianello A, Ambrosetti A, Cantini M, Olivieri O, Dima F, **De Franceschi L**. Blood smear, a key diagnostic tool in hematology: Lesson from two cases of acute hemolysis in previously undiagnosed G6PD deficiency. *Am J Hematol.* 2016 Nov;91(11):1165-1166.
- 116) Lupo F, Tibaldi E, Matte A, Sharma AK, Brunati AM, Alper SL, Zancanaro C, Benati D,

- Siciliano A, Bertoldi M, Zonta F, Storch A, Walker RH, Danek A, Bader B, Hermann A, **De Franceschi L**. A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis. *Blood*. 2016 Dec 22;128(25):2976-2987.
- 117) Stanslowsky N, Reinhardt P, Glass H, Kalmbach N, Naujock M, Hensel N, Lübben V, Pal A, Venneri A, Lupo F, **De Franceschi L**, Claus P, Sternecker J, Storch A, Hermann A, Wegner F. Neuronal Dysfunction in iPSC-Derived Medium Spiny Neurons from Chorea-Acanthocytosis Patients Is Reversed by Src Kinase Inhibition and F-Actin Stabilization. *J Neurosci*. 2016 Nov 23;36(47):12027-12043.
- 118) Porreca I, D'Angelo F, **De Franceschi L**, Mattè A, Ceccarelli M, Iolascon A, Zamò A, Russo F, Ravo M, Tarallo R, Scarfò M, Weisz A, De Felice M, Mallardo M, Ambrosino C. Pesticide toxicogenomics across scales: in vitro transcriptome predicts mechanisms and outcomes of exposure in vivo. *Sci Rep*. 2016 Dec 1;6:38131.
- 119) Millot S, Delaby C, Moulouel B, Lefebvre T, Pilard N, Ducrot N, Ged C, Lettèron P, **de Franceschi L**, Deybach JC, Beaumont C, Gouya L, De Verneuil H, Lyoumi S, Puy H, Karim Z. Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model. *Haematologica*. 2017 Feb;102(2):260-270. doi: 10.3324/haematol.2016.151621.
- 120) Ingoglia G, Sag CM, Rex N, **De Franceschi L**, Vinchi F, Cimino J, Petrillo S, Wagner S, Kreitmeier K, Silengo L, Altruda F, Maier LS, Hirsch E, Ghigo A, Tolosano E. Hemopexin counteracts systolic dysfunction induced by heme-driven oxidative stress. *Free Radical Biol Med*. 2017 Jul;108:452-464.
- 121) Than NN, Soe HHK, Palaniappan SK, Abas AB, **De Franceschi L**. Magnesium for treating sickle cell disease. *Cochrane Database Syst Rev*. 2017 Apr 14;4:CD011358
- 122) **De Franceschi L**, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. *Eur J Intern Med*. 2017 Jul;42:16-23.
- 123) Iolascon A, Andolfo I, Barcellini W, Corcione F, Garçon L, **De Franceschi L**, Pignata C, Graziadei G, Pospisilova D, Rees DC, de Montalembert M, Rivella S, Gambale A, Russo R, Ribeiro L, Vives-Corrons J, Martinez PA, Kattamis A, Gulbis B, Cappellini MD, Roberts I, Tamary H; Working Study Group on Red Cells and Iron of the EHA. Recommendations regarding splenectomy in hereditary hemolytic anemias. *Haematologica*. 2017 Aug;102(8):1304-1313.
- 124) Ingoglia G, Sag CM, Rex N, **De Franceschi L**, Vinchi F, Cimino J, Petrillo S, Wagner S, Kreitmeier K, Silengo L, Altruda F, Maier LS, Hirsch E, Ghigo A, Tolosano E. Data demonstrating the anti-oxidant role of hemopexin in the heart. *Data Brief*. 2017 May 13;13:69-76.
- 125) Matte A, De Falco L, Federti E, Cozzi A, Iolascon A, Levi S, Mohandas N, Zamo A, Bruno M, Lebouef C, Janin A, Siciliano A, Ganz T, Federico G, Carlomagno F, Mueller S, Silva I, Carbone C, Melisi D, Kim DW, Choi SY, **De Franceschi L**. Peroxiredoxin-2: A Novel Regulator of Iron Homeostasis in Ineffective Erythropoiesis. *Antioxid Redox Signal*.

2017 Sep 6. doi: 10.1089/ars.2017.7051. [Epub ahead of print] PubMed PMID: 28793778.

- 126) Federti E, Matte A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, Melisi D, Kim DW, Levi S, **De Franceschi L**. Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. *Data Brief*. 2017 Sep 30;15:376-381. doi:10.1016/j.dib.2017.09.062. eCollection 2017 Dec. PubMed PMID: 29034295;
- 127) Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, **De Franceschi L**, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. *Am J Hematol*. 2017 Dec;92(12):1349-1355. doi:10.1002/ajh.24911. Epub 2017 Oct 19. PubMed PMID: 28929515.
- 128) Federti E, Matté A, Ghigo A, Andolfo I, James C, Siciliano A, Leboeuf C, Janin A, Manna F, Choi SY, Iolascon A, Beneduce E, Melisi D, Kim DW, Levi S, **De Franceschi L**. Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension. *Free Radic Biol Med*. 2017 Nov;112:376-386. doi: 10.1016/j.freeradbiomed.2017.08.004. Epub 2017 Aug 9. PubMed PMID: 28801243.
- 129) Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, **De Franceschi L**, Scarpa A, Tortora G, Melisi D. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. *Int J Obes (Lond)*. 2018 Mar;42(3):334-343. doi: 10.1038/ijo.2017.285. Epub 2017 Nov 20. PubMed PMID: 29151594; PubMed Central PMCID: PMC5880584.
- 130) Rigano P, **De Franceschi L**, Sainati L, Piga A, Piel FB, Cappellini MD, Fidone C, Masera N, Palazzi G, Gianesin B, Forni GL; Italian Multicenter Study of Hydroxyurea in Sickle Cell Anemia Investigators. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. *Blood Cells Mol Dis*. 2018 Mar;69:82-89. doi: 10.1016/j.bcmd.2017.08.017. Epub 2017 Oct 9. PubMed PMID: 29107441.
- 131) Dal Zotto C, Wieczorek M, Mariottini G, Malagò R, Olivieri O, **De Franceschi L**. Persistent abdominal pain related to portal vein thrombosis in young adults with sickle cell disease. *Am J Hematol*. 2018 Dec;93(12):1562-1565. doi:10.1002/ajh.25291. Epub 2018 Oct 15. PubMed PMID: 30230563.
- 132) Pinto VM, Balocco M, Quintino S, Bacigalupo L, Gianesin B, Rizzi M, Malagò R, **De Franceschi L**, Forni GL. Daily alternating deferasirox and deferiprone therapy successfully controls iron accumulation in untreatable transfusion-dependent thalassemia patients. *Am J Hematol*. 2018 Oct;93(10):E338-E340. doi: 10.1002/ajh.25222. Epub 2018 Aug 14. PubMed PMID: 30033633.
- 133) Vianello A, Vencato E, Cantini M, Zanconato G, Manfrin E, Zamo A, Zorzi F, Mazzi F,

- Martinelli N, Cavaliere E, Monari F, Venturelli D, Ferrara F, Olivieri O, **DeFranceschi L**. Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis. *Transfusion*. 2018Sep;58(9):2192-2201. doi: 10.1111/trf.14767. Epub 2018 Jul 8. PubMed PMID: 29984534.
- 134) **De Franceschi L**, Iolascon A, Taher A, Cappellini MD. Microcytosis is important in screening of iron deficiency anemia. *Eur J Intern Med*. 2018 Feb;48:e39. doi: 10.1016/j.ejim.2017.08.021. Epub 2018 Feb 1. PubMed PMID: 29361474.
- 135) Pinto VM, Bacigalupo L, Giancesin B, Balocco M, **De Franceschi L**, Malagò R, Wood J, Forni GL. Lack of correlation between heart, liver and pancreas MRI-R2*: Results from long-term follow-up in a cohort of adult β -thalassemia major patients. *Am J Hematol*. 2018 Mar;93(3):E79-E82. doi: 10.1002/ajh.25009. Epub 2018 Jan 9. PubMed PMID: 29265491.
- 136) Andolfo I, Manna F, De Rosa G, Rosato BE, Gambale A, Tomaiuolo G, Carciati A, Marra R, **De Franceschi L**, Iolascon A, Russo R. PIEZO1-R1864H rare variant accounts for a genetic phenotype-modifier role in dehydrated hereditary stomatocytosis. *Haematologica*. 2018 Mar;103(3): e94-e97. doi: 10.3324/haematol.2017.180687.
- 137) Matte A, **De Franceschi L**. Oxidation and erythropoiesis. *Curr Opin Hematol*. 2019 Mar 6. doi: 10.1097/MOH.0000000000000495. [Epub ahead of print].
- 138) **De Franceschi L**, Lux C, Piel FB, Giancesin B, Bonetti F, Casale M, Graziadei G, Lisi R, Pinto V, Putti MC, Rigano P, Rosso R, Russo G, Spadola V, Pulvirenti C, Rizzi M, Mazzi F, Ruffo G, Forni GL. Access to emergency department for acute events and identification of sickle cell disease in refugees. *Blood*. 2019 Feb 11. pii:blood-2018-09-876508. doi: 10.1182/blood-2018-09-876508.
- 139) Matte A, Zorzi F, Mazzi F, Federti E, Olivieri O, **De Franceschi L**. New Therapeutic Options for the Treatment of Sickle Cell Disease. *Mediterr J Hematol Infect Dis*. 2019 Jan 1;11(1): e2019002. doi: 10.4084/MJHID.2019.002. eCollection2019. Review. PubMed PMID: 30671208; PubMed Central PMCID: PMC6328043.
- 140) Galvani C, Caramaschi P, Mura P, Paladini A, Piroli A, Arnaudo E, **De Franceschi L**, Evangelista M, Pari A, Ongaro G, Finco G, Ciannone A, Carletto A, Varrassi G, Biasi D. Postural counseling represents a novel option in pain management of fibromyalgia patients. *J Pain Res*. 2019 Jan 11;12:327-337. doi: 10.2147/JPR.S164714. eCollection 2019. Erratum in: *J Pain Res*. 2019 Mar 11;12:951. PubMed PMID: 30666151; PubMed Central PMCID: PMC6333156.
- 141) Franchini M, Forni GL, Marano G, Cruciani M, Mengoli C, Pinto V, **De Franceschi L**, Venturelli D, Casale M, Amerini M, Capuzzo M, Grazzini G, Masiello F, Pati I, Veropalumbo E, Vaglio S, Pupella S, Liembruno GM. Red blood cell alloimmunization in transfusion-dependent thalassaemia: a systematic review. *Blood Transfus*. 2019 Jan;17(1):4-15. doi: 10.2450/2019.0229-18.
- 142) Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, **De Franceschi L**. Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule.

Haematologica. 2019 Jan 10. pii: haematol.2018.198622. doi: 10.3324/haematol.2018.198622.

- 143) Matte A, Recchiuti A, Federti E, Koehl B, Mintz T, El Nemer W, Tharaux PL, Brousse V, Andolfo I, Lamolinara A, Weinberg O, Siciliano A, Norris PC, Riley IR, Iolascon A, Serhan CN, Brugnara C, **De Franceschi L**. Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. *Blood*. 2019 Jan 17;133(3):252-265. doi: 10.1182/blood-2018-07-865378. Epub 2018 Nov 7.
- 144) Beneduce E, Matte A, De Falco L, Mbiandjeu S, Chiabrando D, Tolosano E, Federti E, Petrillo S, Mohandas N, Siciliano A, Babu W, Menon V, Ghaffari S, Iolascon A, **De Franceschi L**. Fyn kinase is a novel modulator of erythropoietin signaling and stress erythropoiesis. *Am J Hematol*. 2019 Jan;94(1):10-20. PubMedPMID: 30252956.
- 145) Iolascon A, **De Franceschi L**, Muckenthaler M, Taher A, Rees D, de Montalembert M, Rivella S, Eleftheriou A, Cappellini MD. EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. *Hemasphere*. 2019 Jun 4;3(3):e208.
- 146) Matte A, Federti E, Winter M, Koerner A, Harmeier A, Mazer N, Tomka T, Di Paolo ML, De Falco L, Andolfo I, Beneduce E, Iolascon A, Macias-Garcia A, Chen JJ, Janin A, Lebouef C, Turrini F, Brugnara C, **De Franceschi L**. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β -thalassemia. *JCI Insight*. 2019 Nov 14;4(22).
- 147) Abruzzo PM, Matté A, Bolotta A, Federti E, Ghezzi A, Guarnieri T, Marini M, Posar A, Siciliano A, **De Franceschi L**, Visconti P. Plasma peroxiredoxin changes and inflammatory cytokines support the involvement of neuro-inflammation and oxidative stress in Autism Spectrum Disorder. *J Transl Med*. 2019 Oct 2;17(1):332.
- 148) Than NN, Soe HHK, Palaniappan SK, Abas AB, **De Franceschi L**. Magnesium for treating sickle cell disease. *Cochrane Database Syst Rev*. 2019 Sep 9;9:CD011358.
- 149) Scambi C, Ugolini S, Tonello M, Bortolami O, **De Franceschi L**, Castagna A, Lotti V, Corbella M, Raffaelli R, Caramaschi P, Mattia E, Biasi D, Ruffatti A. Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. *Am J Reprod Immunol*. 2019 Dec;82(6):e13185.
- 150) Russo G, **De Franceschi L**, Colombatti R, Rigano P, Perrotta S, Voi V, Palazzi G, Fidone C, Quota A, Graziadei G, Pietrangelo A, Pinto V, Ruffo GB, Sorrentino F, Venturelli D, Casale M, Ferrara F, Sainati L, Cappellini MD, Piga A, Maggio A, Forni GL. Current challenges in the management of patients with sickle cell disease - A report of the Italian experience. *Orphanet J Rare Dis*. 2019 May 30;14(1):120.
- 151) Andolfo I, De Rosa G, Errichiello E, Manna F, Rosato BE, Gambale A, Vetro A, Calcaterra V, Pelizzo G, **De Franceschi L**, Zuffardi O, Russo R, Iolascon A. PIEZO1 Hypomorphic Variants in Congenital Lymphatic Dysplasia Cause Shape and Hydration Alterations of Red Blood Cells. *Front Physiol*. 2019 Mar 15;10:258. doi: 10.3389/fphys.2019.00258. PMID: 30930797; PMCID: PMC6428731.

- 152) Tibaldi E, Federti E, Matte A, Iatcenko I, Wilson AB, Riccardi V, Pagano MA, **De Franceschi L**. Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders. *Antioxidants (Basel)*. 2020 Apr 24;9(4). pii: E353. doi: 10.3390/antiox9040353. Review. PubMed PMID: 32344529.
- 153) Motta I, Migone De Amicis M, Pinto VM, Balocco M, Longo F, Bonetti F, Gianesi B, Graziadei G, Cappellini MD, **De Franceschi L**, Piga A, Forni GL. SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience. *Am J Hematol*. 2020 Apr 20. doi: 10.1002/ajh.25840. 32311145.
- 154) Park SY, Matte A, Jung Y, Ryu J, Wilson AB, Han EYA, Liu M, Carbone C, Melisi D, Nagasawa T, Locascio JJ, Lin CP, Silberstein LE, **De Franceschi L**. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion. *Blood*. 2020 Jan 27. pii: blood.2019002227doi:10.1182/blood.2019002227.
- 155) Matte A, Cappellini MD, Iolascon A, Enrica F, **De Franceschi L**. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? *Expert Opin Investig Drugs*. 2020 Jan;29(1):23-31. doi: 10.1080/13543784.2020.1703947.
- 156) Shmukler BE, Rivera A, Bhargava P, Nishimura K, Kim EH, Hsu A, Wohlgemuth JG, Morton J, Snyder LM, **De Franceschi L**, Rust MB, Hubner CA, Brugnara C, Alper SL. Genetic disruption of KCC cotransporters in a mouse model of thalassemia intermedia. *Blood Cells Mol Dis*. 2020 Mar;81:102389.
- 157) Faes C, Juban G, Aufradet E, Desgeorges T, Charrin E, Connes P, Mury P, Mattè A, **De Franceschi L**, Martin C, Pialoux V. Effects of hypoxia-reoxygenation stimulation renal redox status and nuclear factor erythroid 2-related factor 2 pathways in sickle cell SAD mice. *Exp Physiol*. 2020 Feb;105(2):357-369.
- 158) **De Franceschi L**, Costa E, Dima F, Morandi M, Olivieri O. Acute hemolysis by hydroxycloquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. *Eur J Intern Med*. 2020 Jul;77:136-137.
- 159) Taher AT, Bou-Fakhredin R, Kreidieh F, Motta I, **De Franceschi L**, Cappellini MD. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations. *Am J Hematol*. 2020 Aug;95(8):E208-E210.
- 160) Pecoraro L, Dalle Carbonare L, **De Franceschi L**, Piacentini G, Pietrobelli A. The psychophysical impact that COVID-19 has on children must not be underestimated. *Acta Paediatr*. 2020 Aug;109(8):1679-1680.
- 161) **De Franceschi L**, Gabbiani D, Giusti A, Forni G, Stefanoni F, Pinto VM, Sartori G, Balocco M, Dal Zotto C, Valenti MT, Dalle Carbonare L. Development of Algorithm for Clinical Management of Sickle Cell Bone Disease: Evidence for a Role of Vertebral Fractures in Patient Follow-up. *J Clin Med*. 2020 May 25;9(5):1601.
- 162) Martinelli N, Montagnana M, Pizzolo F, Friso S, Salvagno GL, Forni GL, Gianesi B, Morandi M, Lunardi C, Lippi G, Polati E, Olivieri O, **De Franceschi L**. A relative ADAMTS13

deficiency supports the presence of a secondary microangiopathy in COVID 19. *Thromb Res.* 2020 Sep;193:170-172.

- 163) **De Franceschi L**, Costa E, Dima F, Morandi M, Olivieri O. Glucose-6- phosphate dehydrogenase deficiency associated hemolysis in COVID-19 patients treated with hydroxychloroquine/chloroquine: New case reports coming out. *Eur J Intern Med.* 2020 Oct;80:103. doi: 10.1016/j.ejim.2020.08.015.
- 164) Mattè A, Lupo F, Tibaldi E, Di Paolo ML, Federti E, Carpentieri A, Pucci P, Brunati AM, Cesaro L, Turrini F, Gomez Manzo S, Choi SY, Marcial Quino J, Kim DW, Pantaleo A, Xiuli A, Iatcenko I, Cappellini MD, Forni GL, De Franceschi L. Fynspecifically Regulates the activity of red cell glucose-6-phosphate dehydrogenase. *Redox Biol.* 2020 Sep;36:101639. doi: 10.1016/j.redox.2020.101639.
- 165) Taher AT, Iolascon A, Matar CF, Bou-Fakhredin R, **De Franceschi L**, Cappellini MD, Barcellini W, Russo R, Andolfo I, Tyan P, Gulbis B, Aydinok Y, Anagnou NP, Bencaiova GA, Tamary H, Martinez PA, Forni G, Vindigni R. Recommendations for Pregnancy in Rare Inherited Anemias. *Hemasphere.* 2020 Aug 12;4(4):e446. doi:10.1097/HS9.0000000000000446.
- 166) Ramírez-Nava EJ, Hernández-Ochoa B, Navarrete-Vázquez G, Arreguín- Espinosa R, Ortega-Cuellar D, González-Valdez A, Martínez-Rosas V, Morales- Luna L, Martínez-Miranda J, Sierra-Palacios E, Rocha-Ramírez LM, **De Franceschi L**, Marcial-Quino J, Gómez-Manzo S. Novel inhibitors of human glucose-6- phosphate dehydrogenase (HsG6PD) affect the activity and stability of the protein. *Biochim Biophys Acta Gen Subj.* 2021 Mar;1865(3):129828. doi: 10.1016/j.bbagen.2020.129828.
- 167) Mattè A, Federti E, Tibaldi E, Di Paolo ML, Bisello G, Bertoldi M, Carpentieri A, Pucci P, Iatcenko I, Wilson AB, Riccardi V, Siciliano A, Turrini F, Kim DW, Choi SY, Brunati AM, **De Franceschi L**. Tyrosine Phosphorylation Modulates Peroxiredoxin-2 Activity in Normal and Diseased Red Cells. *Antioxidants (Basel).* 2021 Feb 1;10(2):206. doi: 10.3390/antiox10020206.
- 168) Pecoraro L, Dalle Carbonare L, **De Franceschi L**, Piacentini G, Pietrobelli A. Cambiamento climatico, inquinamento atmosferico e aumento delle allergie respiratorie: solo una coincidenza o qualcosa di più? [Climate change, air pollution, and increase of respiratory allergies: just a coincidence or something more?]. *Epidemiol Prev.* 2020 Sep-Dec;44(5-6):405-409.
- 169) Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy.* 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021
- 170) Matte A, Federti E, Kung C, Kosinski PA, Narayanaswamy R, Russo R, Federico G, Carlomagno F, Desbats MA, Salviati L, Leboeuf C, Valenti MT, Turrini F, Janin, A, Yu S, Beneduce E, Ronseaux S, Iatcenko I, Dang L, Ganz T, Jung CL, Iolascon A, Brugnara C, **De Franceschi L**. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β -thalassemia mouse model. *J Clin Invest.* 2021 May 17;131(10):e144206. doi: 10.1172/JCI144206. PMID: 33822774; PMCID:

- 171) Peikert K, Federti E, Matte A, Constantin G, Pietronigro EC, Fabene PF, Defilippi P, Turco E, Del Gallo F, Pucci P, Amoresano A, Illiano A, Cozzolino F, Monti M, Garello F, Terreno E, Alper SL, Glaß H, Pelzl L, Akgün K, Ziemssen T, Ordemann R, Lang F, Brunati AM, Tibaldi E, Andolfo I, Iolascon A, Bertini G, Buffelli M, Zancanaro C, Lorenzetto E, Siciliano A, Bonifacio M, Danek A, Walker RH, Hermann A, **De Franceschi L**. Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. *Acta Neuropathol Commun*. 2021 May 3;9(1):81. doi: 10.1186/s40478-021-01181.
- 172) Pecoraro L, Ferruzzi A, **De Franceschi L**, Dalle Carbonare L, Piacentini G, Pietrobelli A. Children and their being "carnivorous": is visceral adiposity protection or promotion? *Minerva Pediatr (Torino)*. 2021 Sep 13. doi: 10.23736/S2724-5276.21.06307-2.
- 173) Baronciani D, Casale M, **De Franceschi L**, Graziadei G, Longo F, Origa R, Rigano P, Pinto V, Marchetti M, Gigante A, Forni GL. Selecting β -thalassemia Patients for Gene Therapy: A Decision-making Algorithm. *Hemasphere*. 2021 Apr 29;5(5):e555. doi: 10.1097/HS9.0000000000000555.
- 174) Peikert K, Glaß H, Federti E, Matte A, Pelzl L, Akgün K, Ziemssen T, Ordemann R, Lang F, Patients TNFTRFN, **De Franceschi L**, Hermann A. Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. *J Pers Med*. 2021 May 10;11(5):392. doi: 10.3390/jpm11050392.
- 175) Valenti MT, Mattè A, Federti E, Puder M, Anez-Bustillos L, Deiana M, Cheri S, Minoia A, Brugnara C, Di Paolo ML, Dalle Carbonare L, **De Franceschi L**. Dietary ω -3 Fatty Acid Supplementation Improves Murine Sickle Cell Bone Disease and Reprograms Adipogenesis. *Antioxidants (Basel)*. 2021 May 18;10(5):799.
- 176) Osti N, Ceolan J, Piccoli P, Mazzi F, Montemezzi R, Dima F, Friso S, Pizzolo F, Martinelli N, Rizzi M, Moruzzi S, Olivieri O, **De Franceschi L**. Acute haemolysis by cold antibody during SARS-CoV-2 infection in a patient with Evans syndrome: a case report and literature review. *Blood Transfus*. 2021 Aug 6. doi: 10.2450/2021.0133-21. Epub ahead of print.
- 177) Iolascon A, Bianchi P, Andolfo I, Russo R, Barcellini W, Fermo E, Toldi G, Ghirardello S, Rees D, Van Wijk R, Kattamis A, Gallagher PG, Roy N, Taher A, Mohty R, Kulozik A, **De Franceschi L**, Gambale A, De Montalembert M, Forni GL, Hartevelde CL, Prchal J; SWG of red cell and iron of EHA and EuroBloodNet. Recommendations for diagnosis and treatment of methemoglobinemia. *Am J Hematol*. 2021 Sep 1. doi: 10.1002/ajh.26340.
- 178) Iolascon A, Rivella S, Anagnou NP, Camaschella C, Swinkels D, Muckenthaler MU, Porto G, Barcellini W, Andolfo I, Risitano AM, Kattamis A, Cappellini MD, Taher AT, **De Franceschi L**, Rees D, Russo R, Tamary H, Stauder R, Girelli D. The EHA Research Roadmap: Anemias. *HemaSphere*. 2021 Jun 30;5(7):e607. doi: 10.1097/HS9.0000000000000607.
- 179) Longo F, Gianesin B, Voi V, Motta I, Pinto VM, Piolatto A, et al. Italian patients with

- hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection. *Am J Hematol.* 2022 Feb 1;97(2):E75-E78.doi: 10.1002/ajh.26429.
- 180) El-Battrawy I, Longo F, Núñez Gil IJ, Abumayyaleh M, Giancesin B, et al. Thalassaemia is paradoxically associated with a reduced risk of in-hospital complications and mortality in COVID-19: Data from an international registry. *J CellMol Med.* 2022 May;26(9):2520-2528. doi:10.1111/jcmm.17026.
- 181) Graziadei G, **De Franceschi L**, Sainati L, Venturelli D, Masera N, et al. Transfusional Approach in Multi-Ethnic Sickle Cell Patients: Real-World PracticeData From a Multicenter Survey in Italy. *Front Med (Lausanne).* 2022 Mar 16;9:832154. doi: 10.3389/fmed.2022.832154.
- 182) Bou-Fakhredin R, **De Franceschi L**, Motta I, Eid AA, Taher AT, Capellini MDRedox Balance in β -Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. *Antioxidants (Basel).* 2022 May 13;11(5):967. doi:10.3390/antiox11050967.
- 183) Pinto VM, Giancesin B, Piel FB, Longo F, Rigano P, Quota A, Spadola V, Graziadei G, Mazzi F, Cappellini MD, Maggio A, Piga A, **De Franceschi L**, ForniGL. Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from 3 decades follow-up in a high-income setting. *Haematologica.* 2022 Aug 4. doi: 10.3324/haematol.2022.280815.
- 184) Carsetti R, Agrati C, Pinto VM, Giancesin B, Gamberini MR, Fortini M, Barella S, Denotti AR, Perrotta S, Casale M, Maggio A, Pitrolo L, Tartaglia E, Piano MortariE, Colavita F, Puro V, Francalancia M, Marini V, Caminati M, Mazzi F, **De Franceschi L**, Forni GL, Locatelli F. Premature aging of the immune system affectsthe response to SARS-CoV-2 mRNA vaccine in β -Thalassemia: additional dose role. *Blood.* 2022 Aug 24:blood.2022017594. doi: 10.1182/blood.2022017594.
- 185) Martinelli N, Rigoni AM, De Marchi S, Osti N, Donini M, Montagnana M, Castagna A, Pattini P, Udali S, **De Franceschi L**, Tinazzi E, Mazzi F, Moruzzi S, Argentino G, Delfino L, Sartori G, Azzini AM, Tacconelli E, Van Dreden P, Lippi G, Girelli D, Olivieri O, Friso S, Pizzolo F. High Plasma Levels of Activated Factor VII- Antithrombin Complex Point to Increased Tissue Factor Expression in Patients withSARS-CoV-2 Pneumonia: A Potential Link with COVID-19 Prothrombotic Diathesis.*Diagnostics (Basel).* 2022 Nov 14;12(11):2792. doi: 10.3390/diagnostics12112792. PMID: 36428852; PMCID: PMC9689539.
- 186) Recchiuti A, Federti E, Matte A, Mazzi F, Ceolan J, Porreca A, Di Nicola M, Menotti S, Alivernini S, **De Franceschi L**. Impaired pro-resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease. *Am J Hematol.* 2022 Dec 20. doi: 10.1002/ajh.26797. Epub ahead of print. PMID: 36540948.
- 187) **De Franceschi L**, Castiglioni C, Condorelli C, Valsecchi D, Premoli E, Fiocchi C, Perrone V, Esposti LD, Forni GL, On Behalf Of The GREATalyS StudyGroup. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.

J Clin Med. 2022 Dec 23;12(1):117. doi: 10.3390/jcm12010117. PMID: 36614918; PMCID: PMC9821386.

- 188) Rossato P, Federti E, Matte A, Glantschnig H, Canneva F, Schuster M, Coulibaly S, Schrenk G, Voelkel D, Dockal M, Plaimauer B, Andolfo I, Iolascon A, Rottensteiner H, Gritsch H, Scheiflinger F, Hoellriegl W, **De Franceschi L**. Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. *Haematologica*. 2022 Nov 1;107(11):2650-2660. doi: 10.3324/haematol.2021.280233. PMID: 35443560; PMCID: PMC9614531.
- 189) Rossato P, Glantschnig H, Canneva F, Schuster M, Coulibaly S, Schrenk G, Voelkel D, Dockal M, Plaimauer B, Rottensteiner H, Gritsch H, Federti E, Matte A, **De Franceschi L**, Scheiflinger F, Hoellriegl W. Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease. *J Thromb Haemost*. 2022 Dec 22:S1538-7836(22)07185-9. doi: 10.1016/j.jth.2022.10.016. Epub ahead of print.
- 190) Federti E, Vinchi F, Iatcenko I, Ghigo A, Matte A, Taya SCM, Siciliano A, Chiabrando D, Tolosano E, Vance SZ, Riccardi V, Andolfo I, Iezzi M, Lamolinara A, Iolascon A, **De Franceschi L**. Duality of Nrf2 in iron-overload cardiomyopathy. *Haematologica*. 2023 Jan 26. doi: 10.3324/haematol.2022.281995. Epub ahead of print. PMID: 36700398.
- 191) Mattè A, Kosinski PA, Federti E, Dang L, Recchiuti A, Russo R, Siciliano A, Riccardi V, Janin A, Mucci M, Leboeuf C, Iolascon A, Brugnara C, **De Franceschi L**. Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β -thalassemic mice. *Haematologica*. 2023 Feb 16. doi: 10.3324/haematol.2022.282614. Epub ahead of print. PMID: 36794508
- 192) Matte A, Federti E, **De Franceschi L**. Erythrocyte pyruvate kinase activation in red cell disorders. *Curr Opin Hematol*. 2023 Feb 10. doi: 10.1097/MOH.0000000000000758. Epub ahead of print. PMID: 36853806.
- 193) Federti E, Matte A, Recchiuti A, Garello F, Ghigo A, [...] **De Franceschi L**. In humanized sickle cell mice, imatinib protects against sickle cell-related injury. *Hemasphere* 7: 3 (e848), 2023. DOI: 10.1097/HS9.0000000000000848.
- 194) Pinto VM, **De Franceschi L**, Giancesin B, Gigante A, Graziadei G, Lombardini L, Palazzi G, Quota A, Russo R, Sainati L, Venturelli D, Forni GL, Origa R. Management of the Sickle Cell Trait: An Opinion by Expert Panel Members. *J Clin Med*. 2023 May 12;12(10):3441. doi: 10.3390/jcm12103441. PMID: 37240547;
- 195) Maule M, Olivieri B, Guarnieri G, **De Franceschi L**, Martinelli N, Vaia R, Argentino G, Vianello A, Senna G, Caminati M. Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach. *J Clin Med*. 2023 Mar 15;12(6):2294. doi:10.3390/jcm12062294.
- 196) Bordoni V, Casale M, Pinto VM, Carsetti R, Giancesin B, Gamberini MR, Mazdai L, Barella S, Denotti AR, Colavita F, Perrotta S, Maggio A, Pitrolo L, Quintino S, Caminati M, Mazzi F, Ceolan J, **De Franceschi L**, Forni GL, Locatelli F, Agrati C. Inflammatory and

- senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients. *Am J Hematol.* 2023 Jun;98(6):E145-E147. doi:10.1002/ajh.26905.
- 197) Matte A, Wilson AB, Gevi F, Federti E, Recchiuti A, Ferri G, Brunati AM, Pagano MA, Russo R, Leboeuf C, Janin A, Timperio AM, Iolascon A, Gremese E, Dang L, Mohandas N, Brugnara C, De Franceschi L. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis. *JCI Insight.* 2023 Oct 23;8(20):e172656. doi: 10.1172/jci.insight.172656.
- 198) Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL; Webthal® project. 'Phenoconversion' in adult patients with β -thalassemia. *Am J Hematol.* 2024 Mar;99(3):490-493. doi: 10.1002/ajh.27194. Epub 2024 Jan 2.
- 199) Pinto VM, Gianesin B, Sardo S, Mazzi F, Baiardi G, Menotti S, Piras F, Quintino S, Robello G, Mattioli F, Finco G, Forni GL, **De Franceschi L.** Safety and efficacy of ketorolac continuous infusion for multimodal analgesia of vaso-occlusive crisis in patients with sickle cell disease. *Orphanet J Rare Dis.* 2024 Jan 22;19(1):22. doi: 10.1186/s13023-023-02998-7.
- 200) Castro OL, De Franceschi L, Ganz T, Kanter J, Kato GJ, Pasricha SR, Rivella S, Wood JC. Iron restriction in sickle cell disease: When less is more. *Am J Hematol.* 2024 Feb 23. doi: 10.1002/ajh.27267.
- 201) Nguyen KA, Matte A, Foresti R, Federti E, Kiger L, Lefebvre C, Hocini H, Pelinski Y, Kitagishi H, Bencheikh L, Pirenne F, **De Franceschi L,** Motterlini R, Bartolucci P. An Oral Carbon Monoxide-Releasing Molecule Protects against Acute Hyper-hemolysis in Sickle Cell Disease. *Blood.* 2024 Mar 22;blood.2023023165. doi: 10.1182/blood.2023023165.
- 202) Costa E, Isgrò A, de Montalembert M, Leufkens HGM, Ware RE, **De Franceschi L.** Successes and pitfalls in orphan drug development for sickle cell disease. *Blood Adv.* 2024 Mar 24;bloodadvances.2023011730. doi: 10.1182/bloodadvances.2023011730.
- 203) Mbiandjeu SCT, Siciliano A, Mattè A, Federti E, Perduca M, Melisi D, Andolfo I, Amoresano A, Iolascon A, Valenti MT, Turrini F, Bovi M, Pisani A, Recchiuti A, Mattoscio D, Riccardi V, Dalle Carbonare L, Brugnara C, Mohandas N, **De Franceschi L.** Nrf2 Plays a Key Role in Erythropoiesis during Aging. *Antioxidants (Basel).* 2024 Apr 12;13(4):454. doi: 10.3390/antiox13040454.
- 204) Pinto VM, Mazzi F, **De Franceschi L.** Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders. *Blood.* 2024 Aug 22;144(8):853-866. doi: 10.1182/blood.2023022193.
- 205) Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, Aguilar Martinez P, Bou-Fakhredin R, Muckenthaler MU, Unal S, Porto G, Ganz T, Kattamis A, **De Franceschi L,** Cappellini MD, Munro MG, Taher A; from EHA-SWG Red Cell and Iron. Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia. *Hemasphere.* 2024 Jul 15;8(7):e108. Doi: 10.1002/hem3.108.

- 206) Caminati M, Carpagnano LF, Alberti C, Amaddeo F, Bixio R, Caldart F, **De Franceschi L**, Del Giglio M, Festi G, [...]. Multidisciplinary Group on rare dysimmune conditions with hyper-Eosinophilia (GEos). Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach. *World Allergy Organ J.* 2024 Jul 25;17(8):100928. doi: 10.1016/j.waojou.2024.100928.
- 207) Giancesin B, Piel FB, de Franceschi L, Forni GL; Italian Haemoglobinopathies National Survey Group. Incorporating national disease burden in GBD estimates of haemoglobinopathies in Italy. *Lancet Haematol.* 2025 Nov;12(11):e857-e859. doi:10.1016/S2352-3026(25)00286-8. PMID: 41193114.
- 208) Agostini V, Henschler R, Lunde THF, Kristoffersen EK, Hetland G, Danilova E, Martin A, Prudent M, Grazzini G, De Franceschi L, Walicka I, Wagner J, Omert L. A validation study of the in vitro performance of hypoxic red blood cells for transfusion across centers in Europe. *Transfusion.* 2025 Dec;65(12):2306-2315. doi: 10.1111/trf.18408. Epub 2025 Oct 30.
- 209) Begali F, Ceolan J, Vitale S, Villaboni S, Merlo M, Zamperini R, Bertazzo R, Luz SR, Mazzi F, De Franceschi L. Intravenous immunoglobulins in the management of acute chest syndrome in two Jehovah's witnesses with sickle cell disease. *Haematologica.* 2025 Oct 2. doi: 10.3324/haematol.2025.287956. Epub ahead of print.
- 210) Hernández-Ochoa B, Gualos-González MG, Moreno-Hernández JA, Morales-Luna L, Vázquez-Bautista M, Canseco-Ávila LM, Pérez de la Cruz V, Arreguin-Espinosa R, Hernández-Urzuá E, Enríquez-Flores S, De la Mora-De la Mora I, Cárdenas-Rodríguez N, Bandala C, De Franceschi L, Vidal-Limon A, Gómez-Manzo S. Integrated Approach for Biochemical and Functional Characterization of Six Clinical Variants of Glucose-6-Phosphate Dehydrogenase. *Int J Mol Sci.* 2025 Aug 30;26(17):8464. doi: 10.3390/ijms26178464.
- 211) Forni GL, Vassanelli A, De Franceschi L, Marson P, Lisi R, Ostuni A, Gigante A, Origa R, Fiorin F. Transfusion strategies in thalassemia and sickle cell disease SITE-SIMTI-SIdEM Good Practice. *Blood Transfus.* 2025 Nov- Dec;23(6):536-554. doi: 10.2450/BloodTransfus.1014.
- 212) Origa R, Giancesin B, Zappu A, Denotti AR, Di Giorgio MA, Sciortino R, Motta I, Panziera DL, Rosso R, Bulla A, Culcasi M, Pasanisi AM, De Franceschi L, Di Maggio R, Pinto VM, Sanna PMG, Ricchi P, Ruffo GB, Schieppati F, Roberti D, Ferrero GB, De Michele E, Arcioni F, Fotzi I, Markt S, Poloni A, Soverini G, Testa ER, Cabiddu G, Fortugno C, Gigante A, Polese F, Rapezzi D, Sau A, Forni GL, Cappellini MD, Longo F. Luspatercept for Transfusion-Dependent Beta- Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy. *Am J Hematol.* 2025 Sep;100(9):1651-1655. doi: 10.1002/ajh.27758.
- 213) Riccardi V, Viscomi CF, Sandri M, D'Alessandro A, Dzieciatkowska M, Stephenson D, Federti E, Hermann A, Salvati L, Siciliano A, Andolfo I, Alper SL, Ceolan J, Iolascon A, Vattemi G, Danek A, Walker RH, Mensch A, Otto M, Deschauer M, Armbrust M, Beninca' C, Salari V, Fabene P, Peikert K, De Franceschi L. Premature skeletal muscle aging in

- VPS13A deficiency relates to impaired autophagy. *Acta Neuropathol Commun.* 2025 Apr 24;13(1):83. doi:10.1186/s40478-025-01997-y.
- 214) De Franceschi L, Angelucci E. "Learn and Know" in the era of gene addition/gene editing based approaches for sickle cell disease: The EHA-EBMT consensus paper. *Bone Marrow Transplant.* 2025 Jun;60(6):749-750. doi: 10.1038/s41409-025-02561-x. Epub 2025 Apr 16.
- 215) Siciliano A, D'Alessandro A, Matte A, Bisello G, Bertoldi M, Dzieciatkowska M, Argabright A, Pozzetto RH, Riccardi V, Mattarei A, Ongaro A, Ceolan J, Russo R, Rivadeneyra L, Wind-Rotolo M, Iolascon A, Brugnara C, De Franceschi L. Mitapivat metabolically reprograms human β -thalassemic erythroblasts, increasing their responsiveness to oxidation. *Blood Adv.* 2025 Jun 10;9(11):2818-2830. doi: 10.1182/bloodadvances.2024013591.
- 216) de Franceschi L, Locatelli F, Rees D, Chabannon C, Dalle JH, Rivella S, Iolascon A, Lobitz S, Abboud MR, de la Fuente J, Flevari P, Angelucci E, de Montalembert M. Selecting patients with sickle cell disease for gene addition or gene editing-based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference. *Hemasphere.* 2025 Mar 13;9(3):e70089. doi: 10.1002/hem3.70089.
- 217) Pinto VM, Cima R, Di Maggio R, Alga ML, Gigante A, Longo F, Pasanisi AM, Venturelli D, Cassinerio E, Casale M, Origa R, Zanconato G, Forni GL, De Franceschi L. Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice. *J Clin Med.* 2025 Feb 1;14(3):948. doi: 10.3390/jcm14030948.
- 218) Federti E, Mattoscio D, Recchiuti A, Matte A, Monti M, Cozzolino F, Iezzi M, Ceci M, Ghigo A, Tolosano E, Siciliano A, Ceolan J, Riccardi V, Gremese E, Brugnara C, De Franceschi L. 17(R)-Resolvin D1 protects against sickle cell- related inflammatory cardiomyopathy in humanized mice. *Blood.* 2025 Apr 24;145(17):1915-1928. doi: 10.1182/blood.2024024768.
- 219) Giancesin B, Piel FB, Musallam KM, Barella S, Casale M, Cassinerio E, Di Maggio R, Gigante A, Gamberini MR, Graziadei G, Lisi R, Longo F, Maggio A, Origa R, Pasanisi A, Perrotta S, Piga AG, Pinto VM, Rosso R, Robello G, Russo G, Zecca M, De Franceschi L, Forni GL, National Survey Group IH. Prevalence and mortality trends of hemoglobinopathies in Italy: a nationwide study. *Haematologica.* 2025 May 1;110(5):1211-1216. doi: 10.3324/haematol.2024.286886. Epub 2025 Jan 23. Erratum in: *Haematologica.* 2025 Jun 1;110(6):1449-1450. doi:10.3324/haematol.2025.287581.
- 220) Bou-Fakhredin R, Cappellini MD, Taher AT, De Franceschi L. Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat. *Am J Hematol.* 2025 Jan;100(1):103-115. doi: 10.1002/ajh.27500. Epub 2024 Oct 14.

Book chapters

- 1) Beuzard Y and **De Franceschi L.** "Experimental Therapies for sickle cell anemia and beta

- thalassemia". In: "Disorders of Hemoglobin" by Steinberg M, Forget B, Higgs D, Nagel R, Cambridge University Press, 1119-1135, 2001.
- 2) **De Franceschi L**, Corrocher R." Erythrocyte membrane anion exchange abnormalities in chorea-acanthocytosis: the band 3 network". In "Neuroacanthocytosis syndromes" by Danek A, Springer Press, 161-169, 2005.
 - 3) **De Franceschi L**, Brugnara C. Experimental treatments for disorders of hemoglobin. In: "Disorders of iron homeostasis, erythrocytes, erythropoiesis" Editors Beaumont C, Beris P, Beuzard Y, Brugnara C. European School of Haematology (ESH) manual, chapter 15, page 335-347, 2006.
 - 4) Bosman G & **De Franceschi L**. Neuroacanthocytosis-related changes in erythrocyte membrane organization and function. In "Neuroacanthocytosis syndromes" by Walker R, Springer Press, page 133-142, 2008
 - 5) Brugnara C, **De Franceschi L**. Transfusion therapy in β thalassemia and sickle cell disease. In: "Chemistry and Biochemistry of Oxygen Therapeutics: from transfusion to Artificial Blood" by Bettani S & Mozzarelli A, John Wiley and Sons Ltd. 2011.
 - 6) De Franceschi L. "Hemoglobinopathies, membranopathies, G6PD deficiency and enzymopathies" Manual **SIMI pocket book**, section 10- Hematology, 2017 edition.
 - 7) De Franceschi L. "Hemoglobinopathies, membranopathies, G6PD deficiency and enzymopathies" Manual **SIMI pocket book**, section 10- Hematology, 2021 edition.
 - 8) **Luzzatto L & De Franceschi L. Hemolytic anemias- Lucio Luzzatto & Lucia De Franceschi", chapter 100; 21st edition of Harrison's Principles of Internal Medicine** (March 2022) (Attachment 2-index-pag. 5)

Patents

- 1) *Canadian Patent*: no 2,308,854. Entitled: use of divalent cations for inhibiting erythrocyte dehydration in vivo.
- 2) *PCT*: WO2003053449A1 (WIPO) Entitled: novel use of 7-monohydroxyethylrutoside (MonoHER) for treatment of haematological disorders, particularly beta-thalassemia.
- 3) *PCT*: /US16/15428 entitled: Modulators of protein tyrosine phosphatase and uses thereof.

INVITED LECTURES

NATIONAL (2000-2025)

- 1) Invited Lecture "Non-oncological hematology" Organized by Prof. Sante Tura, University of Bologna (Bologna, June 2000)
- 2) Invited Lecture for ECM course titled: "Emergencies in Hematology", Niguarda Ca'Granda Hospital. Milan, April 2003.
- 3) Invited Lecture: "Recent progress in thalassemia contribution by animal models and proteomic studies- SIB Riccione 28-30 September 2005
- 4) Invited Lecture: Focus on anemia: "Sickle cell syndromes" – Vicenza hematology days III edition -19-21 October 2005
- 5) Invited Lecture: "Sickle cell syndromes" Conference "Iron overload: clinical aspects and therapy" - Milan 24-25 May 2007
- 6) Invited Lecture "Non-oncological hematology" from prof Sante Tura, University of Bologna and Prof MD Cappellini (Bologna, October 2008)
- 7) Invited Lecture "Epidemiology and clinic of hemoglobinopathies". Rimini 28-31 October 2008- SIBIOC- SIMeL National Congress
- 8) Invited Lecture for post degree course titled "Immigrant anemia". University of Bologna (Organized by Prof Tura and Prof Cappellini); 21-24 November 2010.
- 9) Invited Lecture as part of the educational sessions of the Italian Society of Hematology, Naples 16-19 October 2011
- 10) Invited Lecture "Global care of the subject suffering from hemoglobinopathy" - paper titled: "Global care of the individual suffering from sickle cell anemia" - Milan 29-30 April 2011.
- 11) Invited Lecture by SITE 12 November 2011: "Emergencies in sickle cell anemia".
- 12) Invited Lecture for training course titled: "Non-oncological hematology: new horizons" University of Milano and Italian Society of Hematology; Milan 13-15 March 2012
- 13) Invited Lecture for training course titled: "Iron overload in benign hematological diseases". Paper: "Iron overload in sickle cell anemia". Monza 1 June 2012.
- 14) 27-29 September 2012, Invited Lecture: "How risky that pregnancy" - SITE National Congress, Brindisi
- 15) 20 March 2013, Treviso- Invited Lecture for the SITE meeting at the Treviso Hospital entitled: "Third meeting on the Diagnostics of Hemoglobinopathies. Emerging hemoglobin defects: from the laboratory to the clinic".
- 16) 22-23 March 2013, Milan- Invited Lecture for the meeting titled: "Redefining ferrochelation: aspects of sickle cell disease"
- 17) 12-13 April 2013, Monselice - Invited Lecture for the meeting titled: "Thalassemia: for a systemic and multidisciplinary approach".
- 18) 9-11 June, Rome 2013 - Invited Lecture for the congress of the Italian Society of Pediatric onco-hematology (AIEOP) – Report title: "Sickle cell anemia...everything you wanted to know".
- 19) **Invited Lecture by the Italian Society of Internal Medicine (2013): "Sickle cell anemia an emerging health problem"**

- 20) Invited Lecture: "Stroke in sickle cell syndromes" Workshop-SITE Palermo 10 October 2013
- 21) Invited Lecture at the National Congress of the Italian society for the study of thalassemias and hemoglobinopathies (SITE) Genova 3-5 October 2014
- 22) Invited Lecture: "Hemoglobinopathies"- Benign hematology update – Mantova, 17 October 2014
- 23) Invited Lecture at the Vicenza hematology days:" NON-hematological complications of hemoglobinopathies" Vicenza 19-21 November 2014.
- 24) Invited Lecture at the Meeting:" Red cell biology thirty years after"- relazione:" pathophysiology of sickle cell disease". Milan 24-26 September 2015
- 25) Invited Lecture: SIE (Italian Hematology Society) "Emerging complications of sickle cell anemia" Florence 4-7 October 2015.
- 26) Invited Lecture - Meeting SIGU (Italian Society of Human Genetics)- "Fundamental mechanisms of erythropoiesis"- Rimini 21-23 October 2015
- 27) Invited Lecture for the meeting of the Lombardia hematology network:" new therapies: Drepanocytosis"- Milan 20 April 2016.
- 28) Invited Lecture at the Congress National Congress of the Italian Society for the study of thalassemias and hemoglobinopathies (SITE) Catania 4-7 October 2016
- 29) "Iron and not just iron - hemoglobinopathies and iron pathologies"- Cagliari 11-12 March 2016.
- 30) SIMI – "Triveneto Section: Current affairs in Internal Medicine" - Udine 24 June 2016**
- 31) Congenital migrant anemias: sickle cell anemia. Romagna Hematology Project, Ravenna June 2017
- 32) Highlights from EHA 22-23 September 2017-Florence:" EHA news: Red blood cells"
- 33) SIMI- National Congress. Interactive Courses:" The approach of the patient with anemia in the emergency room". 28 October 2017**
- 34) Invited Lecture;" Sickle cell anemia: new therapeutic approaches"- Highlights in Hematology- Treviso 17 November 2017.
- 35) Invited Lecture:" Drepanocytosis new therapeutic approaches" – Workshop - Prof Sansone-Galliera- 19 January 2018.
- 36) Invited Lecture ECM course:" Focus on hemoglobinopathies, cardiological complications: sickle cell disease and cardiovascular complications"- Modena 22nd June 2018.
- 37) Invited Lecture for University of Padua residential course:" Introduction to translational medicine: from bench side to bedside to the community" 14-18 January 2019
- 38) Post_ASH_SIE:" Hemolytic Anemias", Bologna 14-16 February 2019
- 39) Invited Lecture for the residential course: "Sickle cell anemia and hemoglobinopathies new frontiers", Foggia 26 October 2019
- 40) "Non-malignant hematology: Updates on sickle cell disease"- Firenze 31 January/1st February 2020
- 41) Post-ASH- News from the meeting of the American Society of Hematology, Napoli 13-15 February 2020
- 42) Digital Training Event: "Thalassemias from pathophysiology to treatment perspectives" Report "Complications of hemoglobinopathies". 7 July 2021
- 43) Invited Lecture symposium-SIMI :" Nautilus: Hospital internist discovers the haematological underground". 23 October 2021**
- 44) Invited Lecture: 12-13 November 2021:" Hematological problems in pediatric age - clinical practice". Report:" Kidney alterations and diseases in children with sickle cell disease".

- 45) Post-ASH Genova- Invited Lecture: "News in the treatment of rare anemias" 17-19 February 2022
- 46) SIMTI- Invited Lecture "... not only erythrocytopenia". Rimini 4-5 April 2022
- 47) Non-oncological hematology - Invited Lecture "Therapeutic innovation in Drepanocytosis" Rome 13-14 May 2022
- 48) Invited Lecture "Sickle cell disease: from pathogenesis to therapeutic innovations" in educational workshop on "update on anemia, thrombocytopenia and haemophilia" 20 September 2022
- 49) Invited Lecture -SIE Italian Society of Hematology:" New Pharmacological Approaches in the Treatment of Sickle Cell Anemia" 26-28 September 2022 Rome
- 50) Invited Lecture -SIE Italian Society of Hematology -Educational:" Diagnosis of congenital anemia in adults" - 26-28 September 2022 Rome
- 51) Invited Lecture: "Acute chest syndrome, atopy and bronchial hyperactivity"; 1st October 2022- meeting Difficult allergy and asthma day.
- 52) Invited Lecture: "What's new in beta-thalassemia: new therapeutic perspectives, safety and efficacy of new drugs" - meeting BETA NETWORK II "Patient with beta-thalassemia: a look beyond therapy" - Medical Academy - Ferrara, 6 October 2022
- 53) Invited Lecture:" The management of vaso-occlusive crises in SCD"- 21 October 2022 Bolzano-meeting "Difficult Hematology".
- 54) Invited Lecture:" SCD and b-thalassemia" Difficult diagnoses and rare diseases 27-28 ottobre - Villa Camozzi- Bergamo- Istituto M Negri e SIMI Lombardia**
- 55) Invited Lecture:" SCD: Therapy today"- in Highlights in Hematology-18-19 November 2022, Treviso.
- 56) Invited Lecture: 15 December 2022:" Hematological problems in pediatric age - clinical practice". Report:" What's new in SCD: new therapeutic perspectives, safety and efficacy of new drugs".
- 57) Invited Lecture: workshop SIMTI "hemoglobinopathies: transfusion support and new therapeutic approaches". Report:" the diagnosis of sickle cell disease". Bologna, 31 January 2023.
- 58) 8 May 2023- Palermo- Invited Lecture workshop:" Celebrating successes and addressing persistent unmet needs in thalassemia. "New paradigm in the clinical management of SCD".
- 59) 19 May 2023-Catania- Invited Lecture " Drepanocytosis: update", at the meeting "La prevenzione va in porto – Prevention is successful";
- 60) 21-23 September 2023: Invited Lecture at the National SITE Congress: "Sickle cell anemia: something has changed".
- 61) Invited Lecture:" Educational Workshop - Update on Anemia, Thrombocytopenia, and Hemophilia: "Sickle Cell Disease: From Pathogenesis to Therapeutic Innovations".
- 62) Invited Lecture:" Sickle cell disease: new challenges and perspectives in Italy with the recommendations of the Lancet Hematology Commission", "Dedicated research". Rome 20 Nov 2023.
- 63) "Hemoglobinopathies: transfusion support and new therapeutic approaches"; SIMTI PRO- Roma, 1 February 2024
- 64) VII Non-Malignant Hematology Conference – Florence 9-10 February 2024
- 65) Meeting SITE at the Camera dei Deputati – Rome, 13 March 2024
- 66) Drepanocytosis today: from Diagnosis to Treatment – Catania, 24 May 2024
- 67) 45° National Conference on Transfusion Medicine Studies – SIMTI - Rimini 29-31 May 2024
- 68) "Hemorrhagic and thrombotic diseases in pediatric age" An event sponsored by the

- Italian Society of Pediatrics and Siset – Alessandria 19 September 2024
- 69) “Promoting health and equity: the value of participatory approaches between drepanocytosis and blood donation” – Regional Health Service Emilia-Romagna, 28 September 2024
 - 70) Globulo Rosso Meeting 2024 – Napoli 30 September/ October 2024
 - 71) “Rare Hematology – 20 years of experience in Brescia” – Brescia Euroblood Net 8-9 November 2024
 - 72) “Hematological problems of children and adults: Clinical Practice” – 15-16 November 2024 - Palermo
 - 73) Hematology Passport 2023-2026 – Webinar Non-neoplastic hematology, anemia, hemoglobinopathies and highlights from other pathologies – European Hematology Association – November 2024
 - 74) “New treatment strategies for transfusion dependent anemia” – Hospital dell’Angelo (Venice - Mestre) – 19 December 2024
 - 75) Garden (Global Hematological Rare Disease Alliance) Kick Off Meeting Webinar – Panel Discussant – 24-25 January 2025
 - 76) Speaker at the Round Table “EREDITA’ E RIVOLUZIONE: Le donne che hanno fatto la storia e quelle che la stanno riscrivendo” – Verona 12 March 2025
 - 77) Moderator at the Allergy Forum – “Novità in tema di malattie rare di comune riscontro per l’allergologo-immunologo clinico” – Verona 13 March 2025
 - 78) EHA Business Meeting of SWG red cells and iron – “Breaking new ground: Revolutionary Drugs Shaping Erythropoiesis” – 12 June 2025
 - 79) Invited lecture at the XIV National Congress SITE titled “Sindrome falcemica: scambio eritrocitario, incognite e certezze” – Rome 11-13 September 2025
 - 80) Invited Lecture at the 52° National Congresso SIE titled “Epidemiologia, fisiopatologia clinica e percorso terapeutico nella sindrome falcemica” – Milan 20-22 October 2025
 - 81) “Malattie ematologiche” – Invited Lecture at the Training Course “Medicina delle Migrazioni: tra prevenzione e cura” – AOUI Verona – 20 November 2025

INTERNATIONAL (2000-2023) (n=50)

NB: Invited Seminars held during the PHD Course are not listed here below.

- 1) Invited Lecture: European School of Hematology (ESH): "Iron Metabolism, erythropoiesis and related disorders", Sestri Levante 15-17 October 2004.
- 2) Invited Lecture - French Hematology Society: "Developing treatments for sickle cell disease"- Paris, February 2004.
- 3) Invited Lecture on Invitation European Hematology Association (EHA): "Establish and Experimental pharmacologic treatments for sickle cell disease" Stockholm, June 2005
- 4) Invited Lecture: International workshop on NA: "Red cells in mcleod syndrome" Kyoto, 27-30 October 2006
- 5) Invited Lecture - "Phospho-signaling in red cells" International NA workshop Bethesda 1-2 October 2010
- 6) Invited Lecture at the "International symposium Neurological complications of Sickle Cell Disease". Padova, 26 March 2011
- 7) Lecture: European Hematology Association (EHA) red cell working group: "Animal models for new therapeutic approaches in SCD" 8 June 2011
- 8) 6th Congress: "Sickle cell disease" at the European Parliament of Strasbourg 12-15 April 2011: "Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with SCD".
- 9) First International Symposium on Allogeneic Cellular Gene Therapy in Hemoglobinopathies; Rome 8-11 March 2012
- 10) Invited Lecture 17th Meeting of European Society of neurosonology and cerebral hemodynamics - "Sickle cell disease: a clinical overview". Venice 17-19 May 2012
- 11) Invited lecture: NBIA meeting- "Phosphoproteomic analysis in chorea-acanthocytosis: the Lyn connection" Wein 5 February 2012
- 12) Invited Lecture: EHA SWG- Red cells and erythropoiesis: "Resveratrol accelerates the activation of FOXO3 and ameliorates anemia in beta thalassemic mice" Stockholm 12 - June 2013
- 13) Invited Lecture 5th European symposium on Rare Anemias- "Clinical management of hemoglobinopathies - The sickle cell syndromes" Ferrara, 15-16 Nov 2013
- 14) Lecture: TIF-international meeting on Thalassemia and Hemoglobinopathies. Disturbed transmembrane ion transports and sickle cell disease – Abu Dhabi, 19-13 October 2013
- 15) Invited Lecture: workshop "Haptoglobin/hemopexin intervention in CPB-assisted cardiac surgery and sickle cell disease: rationale and clinical development perspectives - Treatment for SCD: current and new approaches" Bern, 12-14 Nov. 2014
- 16) Invited lecture: "ESH- Pathophysiology based drug treatment in SCD" Chantilly-France 23-26 April 2014.
- 17) Invited Lecture ESH: "SCD in adult and elderly: emerging complications and management"- Barcelona 23-24 January 2015.
- 18) Invited Lecture EHA-SWG Scientific meeting: Focus on Red Cell and Iron Disorders, and Myelodysplastic Syndrome (MDS) - lecture: "Emerging treatment options for SCD"; March 6-8, 2015, Lisbon, Portugal
- 19) Invited Lecture EHA-SWG Scientific meeting: Focus on Red Cell and Iron

- Disorders, and Myelodysplastic Syndrome (MDS)- lecture:” Clinical guidelines for diagnostics and management: Sickle cell disease- challenges in management; March 6-8, 2015, Lisbon, Portugal
- 20) Invited Lecture SCiF (Sickle cell international focus) - Kings College, London 15-16 June 2015
 - 21) Invited Lecture:” Guidelines on iron overload in rare anemias” - EHA red cell working group 20 June 2016.
 - 22) Lecture. International Society of Laboratory Hematology (ISLH); “Red cells in neuroacanthocytosis”, Milan 2016
 - 23) American Society of Hematology Congress (ASH) ASH- Meeting in San Diego, Dec. 2016: Invited Lecture in Section “Red Cell Biology and Childhood blood disease”.
 - 24) European hematology association (EHA)- scientific working group:” January 2017:”DNA modulators and gene therapy”, Barcellona, Spain.
 - 25) 9th International meeting on neuroacanthocytosis: 23-25 March 2017 Dresden, Germany:” Impaired autophagy is combined with abnormal signal transduction in chorea-acantocytosis”.
 - 26) Invited lecture:” Red cells and oxidative stress- ESH, Paris 18-20 April 2018.
 - 27) Invited lecture: “SCD in adult and elderly: emerging complications and management, Paris Necker SCD preceptorship” Necker, Paris 15-16 Nov 2018.
 - 28) European hematology association (EHA)- scientific working group:” Novel treatments in Sickle cell disease”, Madrid 2019
 - 29) European School of Hematology: Budapest 15-17 March 2019:” Acute sickling crisis”
 - 30) EHA annual meeting- science in focus session:” Autophagy and terminal erythroid differentiation”. 17 June 2020
 - 31) EHA-guidelines workshop: Guideline in management of pregnancy in rare inherited anemias:” Sickle cell disease”. 25 Nov 2020.
 - 32) EHA Hematology passport 2019-2022:” report:” Sickle cell disease” 15 December 2020
 - 33) European School of hematology:” 5-7 March 2021:” New approaches to the management of SCD”.
 - 34) Invited Lecture:” Mouse model for ChAc” 10th International meeting on Neuroacanthocytosis Syndromes, Barcellona 12-15 March 2021
 - 35) Current challenges in hematology (C-Hem2021) 18-19 March 2021:” Clinical Management of Sickle cell disease in 2021”.
 - 36) EHA: invited lecture- Session: red cells and iron: Lecture.” Evaluation of novel fetal hemoglobin inducer drug in clinical perspective”. 14-16 June 2021
 - 37) Invited Lecture workshop:” A new era in the management of SCD: crizanlizumab”. Cyprus, 10 July 2021
 - 38) Invited Lecture IASG Annual members meeting- TIF:” The care and cure of adultsickle cell disease: An overview”. 21-22 October 2021
 - 39) Invited Lecture 15th International conference on thalassemia & other hemoglobinopathies- 17th conference for patients & parents:” Sickle cell disease in adulthood” 19-21 November 2021.

- 40) ASCAT satellite symposium: placeholder - Living with and managing sickle cell disease: patient and physician perspectives—Invited lecture, 26 February 2022.
- 41) EHA meeting – June 2022; Invited Lecture: Joint symposium EHA-ASH: "Olistic approach to patients with SCD"
- 42) EHA meeting – June 2022; Invited Lecture Educational section: "Vasculopathy in SCD"
- 43) Global Sickle cell meeting: Invited Lecture: "SCD and hemolysis"- Paris 16-18 June 2022
- 44) Invited Lecture: "Modern management of sickle cell disease" in International symposium from genes to target therapies in hematology" 1-2 July, 2022 Florence.
- 45) Invited Lecture: "Etiopathogenesis of Herperviscosity of Red Cells and Possible Therapeutic Treatments for Sickle Cell Disorders"- Brazilian Society of Hematology - HEMO2022- 28-29 October 2022
- 46) Invited Lecture EHA SWG red cells and iron business meeting 22 – 24 November 2022; Guidelines on gene therapy/editing in SCD.
- 47) Invited lecture ASH-Highlights 2022: State of the art lecture: "Treatment of sickle cell disease today: challenges and recent advantages". Lebanese Society of Hematology and Blood Transfusion" and the "Lebanese Joint Coalition Against Thrombosis"- 18 March 2023.
- 48) Invited Lecture – 1st symposium on innovative therapies in hematology- Talk: "New treatment options in SCD". Avellino, 30-31 March 2023.
- 49) Invited Lecture - Science-in-Focus Session on "Complement activation in SCD". EHA2023 meeting Frankfurt June 8-11, 2023
- 50) Invited Lecture - Session: "Not-so benign hematological challenges" and give a presentation on "Thrombotic risk and its management in inherited hemoglobin disorders". this session is organized in collaboration with the EHA Specialized Working Group on "Bleeding and thrombosis". EHA2023 meeting Frankfurt June 8-11, 2023.
- 51) Invited lecture- session: "In Vps13a^{-/-} mice, the impairment of autophagy exacerbates skeletal muscle aging phenotype" 11 International meeting on neuroacanthocytosis syndromes -15-17 September 2023 Homburg/Saar, Germany.
- 52) Invited lecture EHA SWG-Budapest: "clinical management of pain in SCD" Budapest 12-14 October 2023
- 53) Invited lecture at Sickle cell in focus conference- NIH "Mouse model of SCD" Oct 10-11, 2023
- 54) Invited lecture at ASH meeting: "The role of complement activation in complication of sickle cell disease" San Diego 8-12 Dec 2023.
- 55) "4th International Symposium on Erythrocyte Biology and 3rd Yellow River Hematology Forum"; ISEB – Zhengzhou China 11-12-13 October 2024
- 56) Invited Lecture at the 4^o Translational Research Conference – "Aging and Sickle Cell Disease" – Dublin 14-16 March 2025
- 57) Invited Lecture at the 12th International Meeting on Neuroacanthocytosis, Cohen syndrome and other VPS13-related disorders" – Lausanne 12-14 September 2025
- 58) Invited Lecture online at the Haematology Nurses & Healthcare Professional Group Educational Conference (Hnhcp) – "Update on pathophysiology & treatment on Sickle Cell Disease" – 8 November 2025
- 59) Invited Lecture at the Haemoglobinopathies Working Party Educational Course – "Ineffective erythropoiesis" – 25-26 November 2025 – Germany

MEETING ORGANIZATION

International Meeting

- 2014- "3rd International Symposium on neuroacanthocytosis and NBIA disease"; 30 Oct-1 Nov 2014 Stresa; Italia.
- Global Sickle cell meeting- Paris 16-18 June 2022

National Meeting

- IX SITE National Congress - Catania 6-8 October 2016
- Globulo Rosso & SITE Meeting – Naples, 28-29 September 2017
- X SITE National Congress - Rome 27-29 September 2018
- Coordination of the educational session "Sickle cell anemia" at the Italian Hematology Society congress (SIE), 7-9 October 2019.
- Globulo Rosso & SITE Meeting – Milano, 26-27 September 2019
- XI SITE National Congress - Mod Virtual 24-26 September 2020
- XII SITE National Congress - Rome, 23-25 September 2021.

EDITORIAL BOARD MEMBER

- 2025 up to date: Member of the Editorial Board Hemasphere (IF12)
- **2015-2020:** Member of the editorial board of BLOOD (IF26.6),
- **2012- to date:** Member of the advisory editorial board of Am J Hematology (IF 13.8),
- **2018- 2020** Co-Editor Frontiers in Immunology- Research Topic Signaling pathways in autoimmune neoplastic and vascular disorders (IF 8.786)
- **2015- to date:** Review Editor- Frontiers in drug metabolism and transport (IF 5.988)
- **2015- to date:** Associated Editor Frontiers in Red cell Physiology (IF 4.755)
- **2008- to date:** Editorial board di Blood Mol Cell Dis (IF 2.9).

REVIEWER ACTIVITIES FOR PEER-REVIEW JOURNALS

- **Blood (IF26.6)- the review activity is reported here: 42 papers**
- Lancet Hematology (IF 18.959): **1**
- **Am J Hematology (IF 13.8): the review activity is reported here: 6 papers**
- **Haematologica (IF 11.8)- the review activity is reported here: 36 papers**
- **British Journal of Haematology (IF 8.61)- the review activity is reported here: 3 papers**
- HemaSphere (IF 8.3): **2 paper**
- Experimental Hematology (IF3.84): **1 paper**
- Frontiers in Frontiers in Red cell Physiology (IF 4.755): **1 paper**
- Scientific Reports (IF4.37): **1 paper**
- PlosOne (IF 3.534): **2 papers**
- Blood Mol Cell Dis (IF 2.9): **the review activity is reported here: 15 papers**
- **From 2002- To date:** Member of the panel review of the **Cochrane Cystic fibrosis and genetic disorders group** for therapeutic problems relating to sickle cell anemia and haemoglobinopathies.

REVIEWER ACTIVITY IN NATIONAL AND INTERNATIONAL MEETING

- SITE National Congress: 2014, 2016, 2018, 2020
- SIE (Italian Society of Hematology) National Congress: 45°, 46°, 47°, 49° congress
- Congress EHA 2018
- Congress ASH 2010 in which she also carried out coordination activities for the panel of reviewers, ASH 2023.

MEMBERSHIP

- Italian Society of Internal Medicine (SIMI)
- COLMED09
- Italian Society of Hematology (SIE)
- Italian society for the study of haemoglobinopathies and thalassemias (SITE)
- European Society of clinical investigation (1994-2000)
- European Hematology Association (EHA)
- American Society of Hematology (ASH).

MEDICAL ASSISTANCE ACTIVITIES

From 1993 to 1998, except for periods of time dedicated exclusively to research, she has always provided full-time care in a hospital setting, responsible for inpatients, day hospitals, outpatients, and interdivisional on-call care at the Department of Medicine, Internal Medicine Section, Policlinico GB Rossi, University of Verona.

Since 1999, she has been providing full-time care in a hospital setting (AOUI Verona) with responsibility for inpatients, day hospitals, and outpatients at the Department of Medicine, Internal Medicine section, University of Verona.

Since 1999, he has provided full-time care in a hospital setting (AOUI Verona), responsible for inpatients, day hospitals, and outpatients at the Department of Medicine, Internal Medicine Section, University of Verona.

Since 2005, in recognition of this expertise, the Verona Hospital Trust has awarded the highly specialized position for "Congenital Hemolytic Anemias".

Since 2021, she has been the coordinator of the GIGAR interdisciplinary group: AOUI Verona, with the creation of 2 integrated clinics: the transition clinic (pediatric age -> adult care - Pediatric Oncohematology) and the high-risk pregnancy clinic in women with rare anemias in collaboration with the obstetrics-gynecology team of AOUI Verona.

From October 2022 - Activation of agreement with the Rovigo Hospital (Ulss5 Polesana) - in-person and telemedicine consultations - discussion of complex cases of congenital anemia.

From October 2025 - Head of USD: Medicine for Benign Immunohematological Rare Diseases (MARIB) - AOUI Verona

Development and implementation of diagnostic and treatment pathways (shared care pathways with the

emergency department and blood transfusion center) for patients with rare hemoglobinopathies or anemias, both in the day care setting and in the general medicine department specializing in immunorheumatology and blood coagulation. Approximately 120 adult patients with organ damage or requiring intensive care are treated annually in the day Service setting (~30% from outside the Region).

SITE-network national reference center for the treatment of rare hemoglobinopathies and anemias.

Since 2016, she has been part of ERN EUROBLOODNET (European Rare Network), the local contact for rare anemias at AOUI Verona, and is actively involved in training (e-learning) and Eurobloodnet (recommendation drafting projects (e.g., recommendation on methemoglobinopathies; Am J Hematol. 2021 Sep 1. doi: 10.1002/ajh.26340. gene therapy-editing in SCD editorial staff).

She also conducts second-level diagnostic activities for rare anemias at the LURM.

As an opinion leader, she sits on the advisory boards of Novartis, Roche, Vifor, and Vertex. She also holds a consulting contract with Novartis.

PI IN THE FOLLOWING CLINICAL STUDIES:

	PROTOCOL NUMBER	TITLE	PHASE	DRUG	Status
ASTRAZENE CA	D5136C00008	A randomised, double-blind, double-dummy, parallel-group, multicenter, phase IIb study to evaluate the effect of ticagrelor 10 mg and 45 mg bid versus placebo in reducing the number of days with pain in young adults with Sickle Cell Disease	IIb	ticagrelor	closed
CELGENE	ACE-536-B-THAL-001	"a phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ace-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia "	III	LUSPATERCEPT (ACE-536)	closed
CELGENE	ACE-536-LTFU-001	A Phase 3B, Open-Label, Single-Arm, Rollover Study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials	IIIb	luspatercept (ACE-536)	Ongoing
GLOBAL BLOOD THERAPEUTICS, INC.	GBT440-031	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease	III	GBT440 capsules or tablets, 300 mg	closed
GLOBAL BLOOD THERAPEUTICS, INC.	GBT440-034	Studio di estensione in aperto di GBT440 somministrato per via orale a pazienti affetti da anemia falciforme che hanno partecipato a sperimentazioni cliniche di GBT440	III	GBT440 capsules or tablets, 300 mg	closed
LA JOLLA PHARMACEUTICAL COMPANY	LJ401-BT01	A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY with ljpc-401 for the treatment of myocardial iron overload in adult patients with transfusion-dependent beta thalassemia	II	LJPC-401	closed
NOVARTIS	CICL670AIC04	Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film-coated tablets in patients completing study CICL670F2201	III	Deferasirox FCT	closed
NOVARTIS	CICL670F2201	ceritinib taken in the fasted state in adult patients with ALK	II	DEFERASIROX	closed
NOVARTIS	CSEG101A2203	A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST)	II	SEG101 crizanlizumab	ongoing
NOVARTIS	CSEG101A23	A phase III, Multicenter, Randomized,	III	SEG101	Clos

	01	Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND) Document type: Clinical Trial Protocol EUDRACT number: 2017-001746-10 Version number: 00 (Original Protocol) Clinical Trial Phase: III Release date: 29-Jan-2019 Property of Novartis Confidential May not be used, divulged, published, or otherwise disclosed without the consent of Novartis Clinical Trial Protocol Template Version 1.0 (13-Dec-2017) This document		crizanlizumab	
NOVARTIS	CSEG101A2401B	Open Study, multicenter, Phase IV, rollover study in patients with sickle cell disease who completed a prior study of crizanlizumab sponsored by Novartis	IV	crizanlizumab	ongoing
NOVARTIS	CSEG101AIT02-SWORLD		Obs	Orizanlizumab	Cancelled by Sponsor
NOVO NORDISK SPA	NN7533-4470	A multicentre trial evaluating the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease - ASCENT 1	II	decitabine - tetrahydrouridine (NDec)	ongoing
PFIZER	C4061002	A Phase 1B, Open-Label, Multiple Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-07059013 in Participants with Sickle Cell Disease	1b	confidential	contact
ROCHE	BO42451	A randomized double-blind phase 2a study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of Crovalimab as adjunct treatment in prevention of acute vaso-occlusive episodes (VOE) in sickle cell disease (SCD)	IIa	Crovalimab	ongoing
ROCHE	BO42452	A phase 1b randomized, placebo-controlled study evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of crovalimab for the management of acute vaso-occlusive episode (VOE), in patients with sickle cell disease (SCD)	1b	Crovalimab	ongoing

VIFOR	VIT_-763- THAL-201	A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VIT-2763 in Subjects with Non-transfusion Dependent Beta-thalassaemia	Ila	VIT-2763	Close
-------	-----------------------	---	-----	----------	-------

EDUCATION & TEACHING ACTIVITIES

Lucia De Franceschi has been and is actively involved in Teaching Activities for master's degree courses in the medical field (Medicine and Surgery, Dentistry and Dental Prosthetics); she participated from 2002 to 2007 in an international university cooperation project at the Université de Ngozi (Burundi) as a lecturer in internal medicine (80-hour course) and she is in charge of the elective course in Medical-anthropological issues in developing countries at the University of Verona; she has been and is involved as a lecturer in specialty schools; she has been and is actively involved in teaching and supervising students of various study courses (medicine and surgery and biotechnology) for the preparation of their degree theses, she has been the tutor of numerous doctoral students as well as research fellows and post-docs. Her constant and continuous commitment to teaching activities also at an international level is evident from her presence in the teaching staff of the European School of Hematology from year 2000 to today.

Furthermore, she has an annual appointment at the Harvard University which requires, in addition to the continuity of research activities, also a cycle of seminars.

AA

AA2022- 2023: Lecturer in the Level I Master's Degree in Thalassemia and Hemoglobinopathies - Università' di Catania (module VI).

AA 2022-2023: member of the scientific committee and teacher (12 hours) Master's degree in Thalassemia and hemoglobinopathies - Università' di Cagliari (UNIVR sede formativa).

AA 2021-2022: Coordination of masterclass 2.0 focus on sickle cell disease. Ente: EDRA spa (<http://www.edracorsi.it/chi-siamo/>)

AA 2020-21: Teaching Advisory Board & masterclass Lecturer" management of hemoglobinopathies" 2020-21 in collaboration with SDA Bocconi (<http://www.masterclasshb.it/faculty.php>)- on behalf of EDRA Spa (<http://www.edracorsi.it/chi-siamo/>).

Below is a summary of the various teaching activities at UNIVR over the last 20 years.

Corsi di studio magistrali a ciclo unico:

- **2000 – 2014** Teaching for the Internal Medicine Module (12 hrs), Corso di Laurea Magistrale in Medicina e Chirurgia, Scuola di Medicina Università di Verona
- **2009 – 2014** Clinical Semiotics Module, Corso di Laurea Magistrale in Medicina e Chirurgia, Scuola di Medicina Università di Verona (24 ore)
- **Dal 2001 up to date** - elective course in Medical-anthropological issues in developing countries (8 hrs).

- **2015 -2022** – Course coordinator in Medical Sciences and lecturer in Internal Medicine (48 hrs frontal lectures and 12 hrs in practical laboratory) - Laurea magistrale ciclo unico in Odontoiatria e protesi dentaria, Scuola di Medicina, Università di Verona
- **2023 – up to date:** Lecturer in Medicina Interna (48 hrs frontal lectures and 12 hrs in practical laboratory) nel corso di Scienze Mediche- Laurea magistrale ciclo unico in Odontoiatria e protesi dentaria, Scuola di Medicina, Università di Verona
- **2025 ad oggi** Lecturer in Medicina Interna (20 hrs frontal lectures) nel corso di Scienze infermieristiche- Laurea magistrale, Università di Verona
- **2000- a tutt'oggi:** Practical teaching-Laurea Magistrale a ciclo unico in Medicina e Chirurgia, Università di Verona nell'ambito dei seguenti insegnamenti: Clinica medica geriatrica e terapia medica; Metodologia Clinica.

INTERNATIONAL EDUCATION AND TEACHING ACTIVITIES

- **AA 2022-23: 12 hours of frontal** lectures in the international cooperation project Hemo-PAL-ISS and the National Blood Center. This is a postgraduate training project to strengthen diagnosis and treatment centers for congenital hemorrhagic diseases and hemoglobinopathies in Palestine (Hemo_Pal) – partner finanziatore Agenzia Italiana per la Cooperazione allo Sviluppo (AICS), Ministero degli Esteri Italiano (allegato 5).
- **AA 2003-2004 up to AA 2007-2008.** Lecturer in Medicina interna (80 hrs, of which 64 frontal e 16 practical activities), Corso di Laurea in Scienze infermieristiche, Università di Ngozi, Burundi, Africa nell'ambito della convenzione tra UNIVR e Università di Ngozi e Amahoro Onlus (allegato 6-certificato).
- **Scuola Europea di Ematologia (ESH):**
 - Invited lecture: “Iron Metabolism, erythropoiesis and related disorders”, Sestri Levante 15/17 October 2004.
 - Invited lecture: “Pathophysiology based drug treatment in SCD” Chantilly- France 23-26 April 2014.
 - SCD in adult and elderly: emerging complications and management”- Barcellona 23-24 January 2015
 - Invited lecture:” Red cells and oxidative stress- ESH, Paris 18-20 April 2018.
- Invited lecture: “SCD in adult and elderly: emerging complications and management”, Paris **Necker SCD preceptorship**, 15-16 Nov 2018.

Scuole di Specialità in ambito medico:

2000 – up to date – Member of the teaching staff of the specialty school in Internal Medicine and of the specialty school in Emergency Medicine and Community Medicine, Università di Verona

2024 up to date – Director of the Scuola di Specilita' in allergologia ed immunologia clinica.

PhD Course

Responsible for organizing annual seminar activities and annual monographic courses.

She holds annual seminars (2 hours) and a monographic course with international teaching staff (12 hours), held annually from 2000 to 2019.

Scientific Committee of the Summer School 24-27 September 2019 entitled: "Blood and Bone" and presentation "Bone disease and hematologic disorders"

- **2015-2020: Coordinator of the Biomolecular Medicine PhD Course**

- **January 2023 up to date: Coordinator of the Biomolecular Medicine PhD Course**

Over the last twenty years, Professor De Franceschi has been the Supervisor for:

- **14** students (5 Triennale Degree and 9 Magistrale Degree)

- **4** Specialità in Medicina Interna.

- **12** doctoral thesis as supervisor e **4** doctoral thesis as co-supervisor

She has acted as a supervisor for 18 post-docs (e.g. Research Fellowship, CoCoCo, Scholarship).

PUBLIC ENGAGEMENT

Lucia De Franceschi has always maintained A close collaborative relationships with associations for patients affected by hemoglobinopathies and rare anemias at a local (e.g., THADREV), national (e.g., UNITED), and European (e.g., TIF) levels, participating as a speaker and/or as a member of scientific dissemination committees, either in-person, virtual or hybrid formats. As a Telethon grant recipient, she has been involved in outreach events, participating in Telethon marathons (e.g., Rai 3 in December 2017) or virtual events organized over the past two years.

Articles, dissemination editorial projects and media:

1998: Highlights and analysis of medical news (www.physweekly.com): Sickle cell disease: fewer crisis after adding magnesium.

2002- 9 december. ASH News:” Exciting new development in pathogenesis and management of red cell disorders to be presented in simultaneous session today”.

2014

- April 2014. Interview Telethon: “ My work alongside patients” <https://www.telethon.it/storie-e-news/storie/ricercatori/lucia-de-franceschi-il-mio-lavoro-al-fianco-dei-pazienti/>

2015

- Article on L’Arena:” The mysterious killer protein and the team of “hunters” funded by Telethon.

2019

- Article on L’Arena:” Stem cell transplant to treat anemia
- Coordination of the thematic table: "Immigration and healthcare" In collaboration with the Pastoral Center for Immigrants-Migrantes - Diocese of Verona and University of Verona, 2019..

2021:

- 27 february 2021 Article on L’Arena:” “Lucia De Franceschi wins Telethon grant”.
- July-August 2021: inserto salute del SOLEVENTIQUATTRORE del

<https://www.sanita24.ilsole24ore.com/vetrina/sfoglio/aviator.php?newspaper=SAQ&issue=20210727&edition=SANITAQUADERNI&startpage=1&displaypages=2>

2022:

- January 2022- il CORRIERE DELLA SERA SALUTE

- 16 September 2022- Interview Radio Verona:” Effects of COVID-19 vaccination on patients with β -thalassemia

202:

- July 2025 – Article on NA News Issue n°48 - Neuroacanthocytosis information and research Titled “New research sheds light on muscle weakness in VPS13A disease”

2026:

- 27/02/2026 – Article on CORRIERE DI VERONA titled “Rare Diseases: A Congenital Anemia Project Launches in Verona”
- 27/02/2026 – Article on LA PIAZZA WEB.IT titled “World Rare Disease Day: Verona Leads the Way in Italy”
- 27/02/2026 – TELEARENA titled “Gentle Transition: A Program for Young People with Rare Blood Diseases”
- 27/02/2026 – Article on DAILY VERONA titled “Rare diseases: Verona leads the way in Italy with its "Patient Journey" program, from childhood to adulthood “
- 28/02/2026 – Article on L’ARENA titled “Rare Diseases: A Project on the Transition to Adulthood”
- 28/02/2026 – Article on VERONASERA titled “AOUI presents “Patient Journey,” the project to provide continuity of care for patients with blood diseases”

The details of some EHA (European Hematology Association) video interviews or informative videos are reported below:

2011

April 2011- Milan: Pharma star:”L’anemia falciforme: la presa in carico”.

<https://www.youtube.com/watch?v=VZ3EQcLi4Kc>

2018

7 December 2018: EHA- Topics in Focus Session 2 “Sickle cell disease”

<https://www.youtube.com/watch?v=m-YBWmyQw7I>

2020:

13 february 2020- PharmaStar;”Anemia falciforme, il punto sulle ultime novità dal congresso americano di ematologia”. <https://www.youtube.com/watch?v=hpwSaqrSBI>

14 february 2020-Pharamastar:” eta-talassemia, le novità in terapia del congresso ASH 2019”.

<https://www.youtube.com/watch?v=zEdEmsJfWqQ>

27 february 2020: Da Verona una scoperta. Telepace-

<https://www.youtube.com/watch?v=7CN6T6XopiY>

27 November 2020: Talassemie ed emoglobinopatie, l’ALT Rino Vullo di Ferrara organizza due giornate di approfondimento in streaming

<https://www.medicalexcellencetv.it/talassemie-ed-emoglobinopatie-lalt-rino-vullo-di-ferrara-organizza-due-giornate-di-approfondimento-in-streaming/>

30 November 2020: Anemia falciforme, stato dell’arte e nuove prospettive terapeutiche- Ematoinfo

<https://www.youtube.com/watch?v=YItKlde1jtk>

2021:

20 may 2021- Quotidiano Sanita'- interview De Franceschi (Verona): "Crizanlizumab allunga il tempo tra una Voc e l'altra in anemia falciforme"

<https://www.popsci.it/anemia-falciforme-sempre-piu-importanti-opzioni-terapeutiche-personalizzate.html>

28 may 2021:" Divulgazione -Talassemia Talk-Associazione Piera Cutino:" L'anemia falciforme: nuove frontiere".

<https://www.youtube.com/watch?v=lom-Pzvamrl>

18 June 2021:" Divulgazione UNITED (federazione associazione dei pazienti)"
DREPANOCITOSI – LA SFIDA DEL FUTURO NEL MONDO DELLE EMOGLOBINOPATIE"

<https://www.unitedonlus.org/drepanocitosi-la-sfida-del-futuro-nel-mondo-delle-emoglobinopatie/>

14 october 2021- Tavola rotonda:" AVIS e Fondazione Telethon: una partnership di valore"- Avis Nazionale-Telethon-

<https://www.youtube.com/watch?v=iEW9gD8yjtY>

15 october 2021: AVIS News:" AVIS e Telethon, 20 anni di impegno per la ricerca

<https://www.avis.it/it/avis-e-telethon-20-anni-di-impegno-per-la-ricerca>

30 october 2021- Pharmastar: :” Anemia falciforme: approvato in Europa crizanlizumab, terapia mirata per le crisi vaso-occlusive”

<https://www.youtube.com/watch?v=ILdYHXQJKwc>

2022:

19 january 2022 Anemia falciforme, arriva in Italia crizanlizumab per la prevenzione delle crisi vaso-occlusive

<https://www.youtube.com/watch?v=SZNMOh7ql3U>

20 january2022

Sky TG24:" Anemia falciforme: in Italia la prima terapia contro le crisi vaso-occlusive

<https://tg24.sky.it/salute-e-benessere/2022/01/20/anemia-falciforme-italia-terapia>

January 2022- Corriere della sera (fonte Italtpress):” Anemia falciforme, una terapia per prevenire le crisi vaso-occlusive

<https://www.quinewspisa.it/italpress/anemia-falciforme-una-terapia-per-prevenire-le-crisi-vaso-occlusive>

2023:

30 January 2023- Telethonitalia instagram – intervista: “una malattia modello tra storia, rivoluzioni

terapeutiche e sostenibilita’. <https://www.instagram.com/tv/CoC9dbFKwS9/?igshid=MDJmNzVkMjY=>

21 april 2023- Talassemia Talk "Nuove frontiere nella terapia per la Drepanocitosi- Fondazione Piera e Francesco Cutino- Guarire dalla talassemia

15 may 2023- articolo divulgativo su OMAR (osservatorio Malattie rare) intervista del giornalista scientifico dr Enrico Orzes:" Deficit di piruvato chinasi, con mitapivat e' possibile ridurre il bisogno di trasfusioni " <https://www.osservatoriomalattierare.it/malattie-rare/deficit-di-piruvato-chinasi/19802->

[deficit-di-piruvato-chinasi-con-mitapivat-e-possibile-ridurre-il-bisogno-di-trasfusioni](#)

2024:

26 september 2024: Dissemination meeting - UNITED Associazione Federativa ETS at la Sala Capitolare di Roma: "Italia, Modello per la Gestione della Drepanocitosi"

<https://unitedonlus.org/diretta-del-convegno-italia-modello-per-la-gestione-della-drepanocitosi/>

28 September 2024: Meeting organized by the Azienda Unità Sanitaria Locale di Reggio Emilia, at the Centro Loris Malaguzzi "Promuovere salute ed equità: Il valore degli approcci partecipativi tra drepanocitosi e dono del sangue"

<https://www.ausl.re.it/promuovere-salute-ed-equita-il-valore-degli-approcci->

12-13 october 2024: DBA Event Onlus *Anemia Diamond Blackfan Italia* ODV, DBA Days 2024 organized at the Hotel l'Hotel Leopardi in Verona, dissemination of scientific research and innovative therapies. <https://amici.fondazionealba.org/eventi/dba-days-2024/>

14 October 2024: Interview for the local News following the DBA Onlus event in Verona "*Tutti insieme per curare la DBA, una rara malattia del sangue*"

<https://tgverona.telenuovo.it/cronaca/2024/10/14/tutti-insieme-per-curare-la-dba-una-rara-malattia-del-sangue>

9 November 2024: Invited Speech for "Patient-Centered Medicine: Sickle Cell Anemia and Thalassemia", an event organized in collaboration with the Azienda Ospedaliero-Universitaria di Modena that took place by the Centro Servizi Facoltà di Medicina e Chirurgia – Modena.

<https://www.aou.mo.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/6338>

Dissemination Publishing Projects:

Ferro e ossidazione nella biocomplessità dell'anemia falciforme

A cura di Lucia De Franceschi e Federica Pilo

Supplemento n.1 a Impact Factor News n.1, anno 2021. Forum Service Editore.

<https://epub.accmcd.org/books/wacn>

She is part of the scientific board of the following patient:

- THADREV: associazione thalassemia e drepanocitosi Verona 9

<https://www.thadrev.com/index.php>

- European sickle cell federation

|W: www.escfederation.eu

F: Federazione europea delle cellule falciformi | Facebook |

T: Federazione europea delle cellule falciformi (@escfederation)

She participates as a speaker at meetings of other patient associations:

Speaker at the national meeting of the national (federated) association (www.

<https://www.unitedonlus.org>), biannually at the meeting for the association Rino Vullo- Ferrara

(<http://www.altferrara.it/joomla3/>), of the association THADREV (<https://www.thadrev.com>) e of the

association DBA onlus Italia (<https://www.fondazionealba.org>).

- Association FASTED (Federation of Sicilian Associations of Thalassemia and Hemoglobinopathies) in Ragusa 25 June 2016,

- associazione Veneta per la lotta alla talassemia (AVLT)- Rovigo:” Medicina personalizzata prospettive nella talassemia”- 20 maggio 2018
- associazione Veneta per la lotta alla talassemia (AVLT)- Rovigo ” Gestione del paziente adulto con talassemia- Verona 17 ottobre 2022.

Collaboration with the PRE.ZI.OSA association (<https://www.associazionepreziosa.it>)

- coordination of the workshop "β-thalassemia: patient perspective and quality of life - Regione Veneto" evento virtuale, 18 November 2021

Coordinating the workshop” New therapies and management of thalassemic patients” and report: “New therapeutic horizons in thalassemia” Hybrid event -Verona-5 november 2022

Verona, 16 March 2026



Lucia De Franceschi